

Customer No. 20350  
TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
(415) 576-0200

Attorney Docket No. 18623-134-1  
Client Ref No. EPI 0134.10US

ASSISTANT COMMISSIONER FOR PATENTS  
BOX PATENT APPLICATION  
Washington, D.C. 20231

"Express Mail" Label No. EL104193879US  
Date of Deposit: November 10, 1998

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

By: 

Sir:

Transmitted herewith for filing is the

- ☐ patent application of
- ☐ continuation patent application of
- ☐ divisional patent application of
- ☒ continuation-in-part patent application of

Inventor(s)/Applicant Identifier: Alessandro Sette, John Sidney, W. Martin Kast, and Scott Southwood

For: HLA BINDING PEPTIDES AND THEIR USES

☒ This application claims priority from each of the following Application Nos./filing dates:

USSN 08/205,713, filed March 4, 1994

the disclosure(s) of which is (are) incorporated by reference.

☐ Please amend this application by adding the following before the first sentence: "This application is a ☐ continuation ☐ continuation-in-part of application No. \_\_\_\_\_, filed \_\_\_\_\_ which are incorporated herein by reference for all purposes."

Enclosed are:

☐ \_\_\_\_\_ sheet(s) of ☐ formal ☐ informal drawing(s).

☐ An assignment of the invention to \_\_\_\_\_

☒ A ☐ signed ☒ unsigned Declaration & Power of Attorney

A ☐ signed ☐ unsigned Declaration.

A Power of Attorney.

A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27 ☐ is enclosed ☐ was filed in the prior application and small entity status is still proper and desired.

☐ A certified copy of a \_\_\_\_\_ application.

☐ Information Disclosure Statement under 37 CFR 1.97.

☐ A petition to extend time to respond in the parent application.

☐ Notification of change of ☐ power of attorney ☐ correspondence address filed in prior application.


☐

In view of the Unsigned Declaration as filed with this application and pursuant to 37 CFR §1.53(b),  
Applicant requests deferral of the filing fee until submission of the Missing Parts of Application.

DO NOT CHARGE THE FILING FEE AT THIS TIME.

Telephone:  
(415) 576-0200

Facsimile:  
(415) 576-0300

  
Ellen Lauver Weber  
Reg No.: 32,762  
Attorneys for Applicant

PATENT APPLICATION

HLA BINDING PEPTIDES AND THEIR USES

Inventor(s):

Alessandro Sette, an Italian citizen  
5551 Linda Rosa Avenue  
La Jolla, CA 92037

John Sidney, a U.S. citizen  
8541 D. Villa La Jolla Drive  
La Jolla, CA 92037

W. Martin Kast, a citizen of The Netherlands  
Maria Rutgersweg106  
Leiden, The Netherlands 2331 NX

Scott Southwood, a U.S. citizen  
10679 Strathmore Dr.  
Santee, CA 92071

Assignee:

Epimmune, Inc.  
San Diego, CA 92121

TOWNSEND AND TOWNSEND AND CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, CA 94111-3834  
(415)576-0200

## HLA BINDING PEPTIDES AND THEIR USES

### REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part of USSN 08/205,713 filed March 4, 1994. The present application is also related to USSN 09/017,735, USSN 08/753,622, USSN 08/822,382, USSN 60/013,980, USSN 08/589,108, USSN 08/454,033, USSN 08/349,177, USSN 08/073,205, and USSN 08/027,146. The present application is also related to USSN 09/017,524, USSN 08/821,739, USSN 60/013,833, USSN 08/758,409, USSN 08/589,107, USSN 08/451,913 and to USSN 08/347,610, USSN 08/186,266, USSN 08/159,339, USSN 09/116,061, USSN 08/103,396, USSN 08/027,746, and USSN 07/926,666. The present application is also related to USSN 09/017,743; USSN 08/753,615; USSN 08/590,298; USSN 08/452,843; USSN 09/115,400; USSN 08/344,824; and USSN 08/278,634. The present application is also related to USSN 08/197,484 and USSN 08/815,396. All of the above applications are incorporated herein by reference.

### BACKGROUND OF THE INVENTION

The present invention relates to compositions and methods for preventing, treating or diagnosing a number of pathological states such as viral diseases and cancers. In particular, it provides novel peptides capable of binding selected major histocompatibility complex (MHC) molecules and inducing an immune response.

MHC molecules are classified as either Class I or Class II molecules. Class II MHC molecules are expressed primarily on cells involved in initiating and sustaining immune responses, such as T lymphocytes, B lymphocytes, macrophages, etc. Class II MHC molecules are recognized by helper T lymphocytes and induce proliferation of helper T lymphocytes and amplification of the immune response to the particular immunogenic peptide that is displayed. Class I MHC molecules are expressed on almost all nucleated cells and are recognized by cytotoxic T lymphocytes (CTLs), which then destroy the antigen-bearing cells. CTLs are particularly important in tumor rejection and in fighting viral infections.

The CTL recognizes the antigen in the form of a peptide fragment bound to the MHC class I molecules rather than the intact foreign antigen itself. The antigen must normally be endogenously synthesized by the cell, and a portion of the protein

antigen is degraded into small peptide fragments in the cytoplasm. Some of these small peptides translocate into a pre-Golgi compartment and interact with class I heavy chains to facilitate proper folding and association with the subunit  $\beta 2$  microglobulin. The peptide-MHC class I complex is then routed to the cell surface for expression and potential recognition by specific CTLs.

Investigations of the crystal structure of the human MHC class I molecule, HLA-A2.1, indicate that a peptide binding groove is created by the folding of the  $\alpha 1$  and  $\alpha 2$  domains of the class I heavy chain (Bjorkman et al., Nature 329:506 (1987). In these investigations, however, the identity of peptides bound to the groove was not determined.

Buus et al., Science 242:1065 (1988) first described a method for acid elution of bound peptides from MHC. Subsequently, Rammensee and his coworkers (Falk et al., Nature 351:290 (1991) have developed an approach to characterize naturally processed peptides bound to class I molecules. Other investigators have successfully achieved direct amino acid sequencing of the more abundant peptides in various HPLC fractions by conventional automated sequencing of peptides eluted from class I molecules of the B type (Jardetzky, et al., Nature 353:326 (1991) and of the A2.1 type by mass spectrometry (Hunt, et al., Science 225:1261 (1992). A review of the characterization of naturally processed peptides in MHC Class I has been presented by Rötzschke and Falk (Rötzschke and Falk, Immunol. Today 12:447 (1991).

Sette et al., Proc. Natl. Acad. Sci. USA 86:3296 (1989) showed that MHC allele specific motifs could be used to predict MHC binding capacity. Schaeffer et al., Proc. Natl. Acad. Sci. USA 86:4649 (1989) showed that MHC binding was related to immunogenicity. Several authors (De Bruijn et al., Eur. J. Immunol., 21:2963-2970 (1991); Pamer et al., 991 Nature 353:852-955 (1991)) have provided preliminary evidence that class I binding motifs can be applied to the identification of potential immunogenic peptides in animal models. Class I motifs specific for a number of human alleles of a given class I isotype have yet to be described. It is desirable that the combined frequencies of these different alleles should be high enough to cover a large fraction or perhaps the majority of the human outbred population.

Despite the developments in the art, the prior art has yet to provide a useful human peptide-based vaccine or therapeutic agent based on this work. The present invention provides these and other advantages.

## SUMMARY OF THE INVENTION

The present invention provides compositions comprising immunogenic peptides having binding motifs for HLA-A2.1 molecules. The immunogenic peptides, which bind to the appropriate MHC allele, are preferably 9 to 10 residues in length and  
 5 comprise conserved residues at certain positions such as positions 2 and 9. Moreover, the peptides do not comprise negative binding residues as defined herein at other positions such as positions 1, 3, 6 and/or 7 in the case of peptides 9 amino acids in length and positions 1, 3, 4, 5, 7, 8 and/or 9 in the case of peptides 10 amino acids in length. The present invention defines positions within a motif enabling the selection of peptides  
 10 which will bind efficiently to HLA A2.1.

The motifs of the inventions include peptide of 9 amino acids which have a first conserved residue at the second position from the N-terminus selected from the group consisting of I, V, A and T and a second conserved residue at the C-terminal position selected from the group consisting of V, L, I, A and M. Alternatively, the  
 15 peptide may have a first conserved residue at the second position from the N-terminus selected from the group consisting of L, M, I, V, A and T; and a second conserved residue at the C-terminal position selected from the group consisting of A and M. If the peptide has 10 residues it will contain a first conserved residue at the second position from the N-terminus selected from the group consisting of L, M, I, V, A, and T; and a second  
 20 conserved residue at the C-terminal position selected from the group consisting of V, I, L, A and M; wherein the first and second conserved residues are separated by 7 residues.

Epitopes on a number of immunogenic target proteins can be identified using the peptides of the invention. Examples of suitable antigens include prostate cancer specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B core and  
 25 surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV1), Kaposi's sarcoma herpes virus (KSHV), human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53 and murine p53 (mp53), CEA, trypanosome surface antigen (TSA), members of the tyrosinase related protein (TRP) families, and Her2/neu. The peptides are thus useful in  
 30 pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

The present invention also provides compositions comprising immunogenic peptides having binding motifs for MHC Class I molecules. The

immunogenic peptides are typically between about 8 and about 11 residues and comprise conserved residues involved in binding proteins encoded by the appropriate MHC allele. A number of allele specific motifs have been identified.

For instance, the motif for HLA-A3.2 comprises from the N-terminus to C-terminus a first conserved residue of L, M, I, V, S, A, T and F at position 2 and a second conserved residue of K, R or Y at the C-terminal end. Other first conserved residues are C, G or D and alternatively E. Other second conserved residues are H or F. The first and second conserved residues are preferably separated by 6 to 7 residues.

The motif for HLA-A1 comprises from the N-terminus to the C-terminus a first conserved residue of T, S or M, a second conserved residue of D or E, and a third conserved residue of Y. Other second conserved residues are A, S or T. The first and second conserved residues are adjacent and are preferably separated from the third conserved residue by 6 to 7 residues. A second motif consists of a first conserved residue of E or D and a second conserved residue of Y where the first and second conserved residues are separated by 5 to 6 residues.

The motif for HLA-A11 comprises from the N-terminus to the C-terminus a first conserved residue of T, V, M, L, I, S, A, G, N, C D, or F at position 2 and a C-terminal conserved residue of K, R, Y or H. The first and second conserved residues are preferably separated by 6 or 7 residues.

The motif for HLA-A24.1 comprises from the N-terminus to the C-terminus a first conserved residue of Y, F or W at position 2 and a C terminal conserved residue of F, I, W, M or L. The first and second conserved residues are preferably separated by 6 to 7 residues.

Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, malignant melanoma antigen (MAGE-1) Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV1), papilloma virus antigens, Lassa virus, mycobacterium tuberculosis (MT), p53 and murine p53 (mp53), CEA, and Her2/neu, and members of the tyrosinase related protein (TRP) families. The peptides are thus useful in pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

The present invention also provides compositions comprising immunogenic peptides having binding motifs for non-A HLA alleles. The immunogenic peptides are preferably about 9 to 10 residues in length and comprise conserved residues at certain positions such as proline at position 2 and an aromatic residue (e.g., Y, W, F) or hydrophobic residue (e.g., L, I, V, M, or A) at the carboxy terminus. In particular, an advantage of the peptides of the invention is their ability to bind to two or more different HLA alleles.

Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, malignant melanoma antigen (MAGE-1) Epstein-Barr virus antigens, human immunodeficiency type-1 virus (HIV1), papilloma virus antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, and Her2/neu. The peptides are thus useful in pharmaceutical compositions for both in vivo and ex vivo therapeutic and diagnostic applications.

### Definitions

The term "peptide" is used interchangeably with "oligopeptide" in the present specification to designate a series of residues, typically L-amino acids, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of adjacent amino acids. The oligopeptides of the invention are less than about 15 residues in length and usually consist of between about 8 and about 11 residues, preferably 9 or 10 residues.

An "immunogenic peptide" is a peptide which comprises an allele-specific motif such that the peptide will bind an MHC molecule and induce a CTL response. Immunogenic peptides of the invention are capable of binding to an appropriate HLA-A2.1 molecule and inducing a cytotoxic T cell response against the antigen from which the immunogenic peptide is derived.

Immunogenic peptides are conveniently identified using the algorithms of the invention. The algorithms are mathematical procedures that produce a score which enables the selection of immunogenic peptides. Typically one uses the algorithmic score with a "binding threshold" to enable selection of peptides that have a high probability of binding at a certain affinity and will in turn be immunogenic. The algorithm is based upon either the effects on MHC binding of a particular amino acid at a particular position

of a peptide or the effects on binding of a particular substitution in a motif containing peptide.

A "conserved residue" is an amino acid which occurs in a significantly higher frequency than would be expected by random distribution at a particular position in a peptide. Typically a conserved residue is one where the MHC structure may provide a contact point with the immunogenic peptide. At least one to three or more, preferably two, conserved residues within a peptide of defined length defines a motif for an immunogenic peptide. These residues are typically in close contact with the peptide binding groove, with their side chains buried in specific pockets of the groove itself. Typically, an immunogenic peptide will comprise up to three conserved residues, more usually two conserved residues.

As used herein, "negative binding residues" are amino acids which if present at certain positions (for example, positions 1, 3 and/or 7 of a 9-mer) will result in a peptide being a nonbinder or poor binder and in turn fail to be immunogenic i.e. induce a CTL response.

The term "motif" refers to the pattern of residues in a peptide of defined length, usually about 8 to about 11 amino acids, which is recognized by a particular MHC allele. The peptide motifs are typically different for each human MHC allele and differ in the pattern of the highly conserved residues and negative residues.

The binding motif for an allele can be defined with increasing degrees of precision. In one case, all of the conserved residues are present in the correct positions in a peptide and there are no negative residues in positions 1,3 and/or 7.

The phrases "isolated" or "biologically pure" refer to material which is substantially or essentially free from components which normally accompany it as found in its native state. Thus, the peptides of this invention do not contain materials normally associated with their in situ environment, e.g., MHC I molecules on antigen presenting cells. Even where a protein has been isolated to a homogenous or dominant band, there are trace contaminants in the range of 5-10% of native protein which co-purify with the desired protein. Isolated peptides of this invention do not contain such endogenous co-purified protein.

The term "residue" refers to an amino acid or amino acid mimetic incorporated in an oligopeptide by an amide bond or amide bond mimetic.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

I. HLA-A2.1 Motif

The present invention relates to the determination of allele-specific peptide motifs for human Class I MHC (sometimes referred to as HLA) allele subtypes, in particular, peptide motifs recognized by HLA-A2.1 alleles. These motifs are then used to define T cell epitopes from any desired antigen, particularly those associated with human viral diseases, cancers or autoimmune diseases, for which the amino acid sequence of the potential antigen or autoantigen targets is known.

Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu.

Peptides comprising the epitopes from these antigens are synthesized and then tested for their ability to bind to the appropriate MHC molecules in assays using, for example, purified class I molecules and radioiodinated peptides and/or cells expressing empty class I molecules by, for instance, immunofluorescent staining and flow microfluorometry, peptide-dependent class I assembly assays, and inhibition of CTL recognition by peptide competition. Those peptides that bind to the class I molecule are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with virally infected target cells or tumor cells as potential therapeutic agents.

The MHC class I antigens are encoded by the HLA-A, B, and C loci. HLA-A and B antigens are expressed at the cell surface at approximately equal densities, whereas the expression of HLA-C is significantly lower (perhaps as much as 10-fold lower). Each of these loci have a number of alleles. The peptide binding motifs of the invention are relatively specific for each allelic subtype.

For peptide-based vaccines, the peptides of the present invention preferably comprise a motif recognized by an MHC I molecule having a wide distribution in the human population. Since the MHC alleles occur at different frequencies within different ethnic groups and races, the choice of target MHC allele may depend upon the

target population. Table 1 shows the frequency of various alleles at the HLA-A locus products among different races. For instance, the majority of the Caucasoid population can be covered by peptides which bind to four HLA-A allele subtypes, specifically HLA-A2.1, A1, A3.2, and A24.1. Similarly, the majority of the Asian population is

5 encompassed with the addition of peptides binding to a fifth allele HLA-A11.2.

TABLE 1

A Allele/Subtype	N(69)*	A(54)	C(502)
A1	10.1(7)	1.8(1)	27.4(138)
A2.1	11.5(8)	37.0(20)	39.8(199)
A2.2	10.1(7)	0	3.3(17)
A2.3	1.4(1)	5.5(3)	0.8(4)
A2.4	-	-	-
A2.5	-	-	-
A3.1	1.4(1)	0	0.2(0)
A3.2	5.7(4)	5.5(3)	21.5(108)
A11.1	0	5.5(3)	0
A11.2	5.7(4)	31.4(17)	8.7(44)
A11.3	0	3.7(2)	0
A23	4.3(3)	-	3.9(20)
A24	2.9(2)	27.7(15)	15.3(77)
A24.2	-	-	-
A24.3	-	-	-
A25	1.4(1)	-	6.9(35)
A26.1	4.3(3)	9.2(5)	5.9(30)
A26.2	7.2(5)	-	1.0(5)
A26V	-	3.7(2)	-
A28.1	10.1(7)	-	1.6(8)
A28.2	1.4(1)	-	7.5(38)
A29.1	1.4(1)	-	1.4(7)
A29.2	10.1(7)	1.8(1)	5.3(27)
A30.1	8.6(6)	-	4.9(25)
A30.2	1.4(1)	-	0.2(1)
A30.3	7.2(5)	-	3.9(20)
A31	4.3(3)	7.4(4)	6.9(35)
A32	2.8(2)	-	7.1(36)
Aw33.1	8.6(6)	-	2.5(13)
Aw33.2	2.8(2)	16.6(9)	1.2(6)
Aw34.1	1.4(1)	-	-
Aw34.2	14.5(10)	-	0.8(4)
Aw36	5.9(4)	-	-

Table compiled from B. DuPont, Immunobiology of HLA, Vol. I, Histocompatibility Testing 1987, Springer-Verlag, New York 1989.

5

\* N - negroid; A = Asian; C = Caucasoid. Numbers in parenthesis represent the number of individuals included in the analysis.

The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they would assume at physiologic pH values, unless otherwise specified. In the amino acid

structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids having D-forms is represented by a lower case single letter or a lower case three letter symbol. Glycine has no asymmetric carbon atom and is simply referred to as "Gly" or G.

The procedures used to identify peptides of the present invention generally follow the methods disclosed in Falk et al., Nature 351:290 (1991), which is incorporated herein by reference. Briefly, the methods involve large-scale isolation of MHC class I molecules, typically by immunoprecipitation or affinity chromatography, from the appropriate cell or cell line. Examples of other methods for isolation of the desired MHC molecule equally well known to the artisan include ion exchange chromatography, lectin chromatography, size exclusion, high performance ligand chromatography, and a combination of all of the above techniques.

In the typical case, immunoprecipitation is used to isolate the desired allele. A number of protocols can be used, depending upon the specificity of the antibodies used. For example, allele-specific mAb reagents can be used for the affinity purification of the HLA-A, HLA-B1, and HLA-C molecules. Several mAb reagents for the isolation of HLA-A molecules are available. The monoclonal BB7.2 is suitable for isolating HLA-A2 molecules. Affinity columns prepared with these mAbs using standard techniques are successfully used to purify the respective HLA-A allele products.

In addition to allele-specific mAbs, broadly reactive anti-HLA-A, B, C mAbs, such as W6/32 and B9.12.1, and one anti-HLA-B, C mAb, B1.23.2, could be used in alternative affinity purification protocols as described in previous applications.

The peptides bound to the peptide binding groove of the isolated MHC molecules are eluted typically using acid treatment. Peptides can also be dissociated from class I molecules by a variety of standard denaturing means, such as heat, pH, detergents, salts, chaotropic agents, or a combination thereof.

Peptide fractions are further separated from the MHC molecules by reversed-phase high performance liquid chromatography (HPLC) and sequenced. Peptides can be separated by a variety of other standard means well known to the artisan, including filtration, ultrafiltration, electrophoresis, size chromatography, precipitation with specific antibodies, ion exchange chromatography, isoelectrofocusing, and the like.

Sequencing of the isolated peptides can be performed according to standard techniques such as Edman degradation (Hunkapiller, M.W., et al., Methods Enzymol. 91, 399 [1983]). Other methods suitable for sequencing include mass spectrometry sequencing of individual peptides as previously described (Hunt, et al.,  
 5 Science 225:1261 (1992), which is incorporated herein by reference). Amino acid sequencing of bulk heterogenous peptides (e.g., pooled HPLC fractions) from different class I molecules typically reveals a characteristic sequence motif for each class I allele.

Definition of motifs specific for different class I alleles allows the identification of potential peptide epitopes from an antigenic protein whose amino acid  
 10 sequence is known. Typically, identification of potential peptide epitopes is initially carried out using a computer to scan the amino acid sequence of a desired antigen for the presence of motifs. The epitopic sequences are then synthesized. The capacity to bind MHC Class molecules is measured in a variety of different ways. One means is a Class I molecule binding assay as described in the related applications, noted above. Other  
 15 alternatives described in the literature include inhibition of antigen presentation (Sette, et al., J. Immunol. 141:3893 (1991), in vitro assembly assays (Townsend, et al., Cell 62:285 (1990), and FACS based assays using mutated cells, such as RMA.S (Melief, et al., Eur. J. Immunol. 21:2963 (1991)).

Next, peptides that test positive in the MHC class I binding assay are  
 20 assayed for the ability of the peptides to induce specific CTL responses in vitro. For instance, antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells (Inaba, et al., J. Exp. Med. 166:182 (1987); Boog, Eur. J. Immunol. 18:219 [1988]).

Alternatively, mutant mammalian cell lines that are deficient in their  
 25 ability to load class I molecules with internally processed peptides, such as the mouse cell lines RMA-S (Kärre, et al., Nature, 319:675 (1986); Ljunggren, et al., Eur. J. Immunol. 21:2963-2970 (1991)), and the human somatic T cell hybrid, T-2 (Cerundolo, et al., Nature 345:449-452 (1990)) and which have been transfected with the appropriate human  
 30 class I genes are conveniently used, when peptide is added to them, to test for the capacity of the peptide to induce in vitro primary CTL responses. Other eukaryotic cell lines which could be used include various insect cell lines such as mosquito larvae (ATCC cell lines CCL 125, 126, 1660, 1591, 6585, 6586), silkworm (ATTC CRL 8851), armyworm

(ATCC CRL 1711), moth (ATCC CCL 80) and *Drosophila* cell lines such as a Schneider cell line (see Schneider *J. Embryol. Exp. Morphol.* 27:353-365 [1927]).

Peripheral blood lymphocytes are conveniently isolated following simple venipuncture or leukapheresis of normal donors or patients and used as the responder cell sources of CTL precursors. In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100  $\mu$ M of peptide in serum-free media for 4 hours under appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the responder cell populations *in vitro* for 7 to 10 days under optimized culture conditions. Positive CTL activation can be determined by assaying the cultures for the presence of CTLs that kill radiolabeled target cells, both specific peptide-pulsed targets as well as target cells expressing the endogenously processed form of the relevant virus or tumor antigen from which the peptide sequence was derived.

Specificity and MHC restriction of the CTL is determined by testing against different peptide target cells expressing appropriate or inappropriate human MHC class I. The peptides that test positive in the MHC binding assays and give rise to specific CTL responses are referred to herein as immunogenic peptides.

The immunogenic peptides can be prepared synthetically, or by recombinant DNA technology or from natural sources such as whole viruses or tumors. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments or particles.

The polypeptides or peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

Desirably, the peptide will be as small as possible while still maintaining substantially all of the biological activity of the large peptide. When possible, it may be desirable to optimize peptides of the invention to a length of 9 or 10 amino acid residues, commensurate in size with endogenously processed viral peptides or tumor cell peptides that are bound to MHC class I molecules on the cell surface.

Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e.g., improved pharmacological characteristics, while

increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell. For instance, the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding. By conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. The effect of single amino acid substitutions may also be probed using D-amino acids. Such modifications may be made using well known peptide synthesis procedures, as described in e.g., Merrifield, Science 232:341-347 (1986), Barany and Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp. 1-284 (1979); and Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984), incorporated by reference herein.

The peptides can also be modified by extending or decreasing the compound's amino acid sequence, e.g., by the addition or deletion of amino acids. The peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e.g., those at critical contact sites or conserved residues, may generally not be altered without an adverse effect on biological activity. The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L- $\alpha$ -amino acids, or their D-isomers, but may include non-natural amino acids as well, such as  $\beta$ - $\gamma$ - $\delta$ -amino acids, as well as many derivatives of L- $\alpha$ -amino acids.

Typically, a series of peptides with single amino acid substitutions are employed to determine the effect of electrostatic charge, hydrophobicity, etc. on binding. For instance, a series of positively charged (e.g., Lys or Arg) or negatively charged (e.g., Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards various MHC molecules and T cell receptors. In addition, multiple substitutions using small, relatively neutral moieties such as Ala, Gly, Pro, or similar residues may be employed. The substitutions may be homo-oligomers or hetero-oligomers. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased binding affinity

for an MHC molecule or T cell receptor may also be achieved by such substitutions, compared to the affinity of the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.

- 5 Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 2 when it is desired to finely modulate
- 10 the characteristics of the peptide.

TABLE 2

<u>Original Residue</u>	<u>Exemplary Substitution</u>
Ala	Ser
Arg	Lys, His
Asn	Gln
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Pro
His	Lys; Arg
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; His
Met	Leu; Ile
Phe	Tyr; Trp
Ser	Thr
Thr	Ser
Trp	Tyr; Phe
Tyr	Trp; Phe
Val	Ile; Leu

Pro

Gly

Substantial changes in function (e.g., affinity for MHC molecules or T cell receptors) are made by selecting substitutions that are less conservative than those in

5 Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which (a)

10 hydrophilic residue, e.g. seryl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (c) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

15 The peptides may also comprise isosteres of two or more residues in the immunogenic peptide. An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence because the steric conformation of the first sequence fits a binding site specific for the second sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art. Such

20 modifications include modifications of the amide nitrogen, the  $\alpha$ -carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, peptides and Proteins, Vol. VII (Weinstein ed., 1983).

25 Modifications of peptides with various amino acid mimetics or unnatural amino acids are particularly useful in increasing the stability of the peptide in vivo. Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokin. 11:291-302 (1986). Half life of the peptides of the present invention is conveniently determined using a 25% human

30 serum (v/v) assay. The protocol is generally as follows. Pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At

predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloroacetic acid or ethanol. The cloudy reaction sample is cooled (4°C) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability-specific chromatography conditions.

The peptides of the present invention or analogs thereof which have CTL stimulating activity may be modified to provide desired attributes other than improved serum half life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Particularly preferred immunogenic peptides/T helper conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. Alternatively, the CTL peptide may be linked to the T helper peptide without a spacer.

The immunogenic peptide may be linked to the T helper peptide either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated. Exemplary T helper peptides include tetanus toxoid 830-843, influenza 307-319, malaria circumsporozoite 382-398 and 378-389.

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes CTL. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the alpha and epsilon amino groups of a Lys residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment a particularly effective immunogen comprises palmitic acid attached to alpha and epsilon amino groups

of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P<sub>3</sub>CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide. See, Deres et al., Nature 342:561-564 (1989), incorporated herein by reference. Peptides of the invention can be coupled to P<sub>3</sub>CSS, for example, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Further, as the induction of neutralizing antibodies can also be primed with P<sub>3</sub>CSS conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to more effectively elicit both humoral and cell-mediated responses to infection.

In addition, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support, or larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide. Modification at the C terminus in some cases may alter binding characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH<sub>2</sub> acylation, e.g., by alkanoyl (C<sub>1</sub>-C<sub>20</sub>) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

The peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed., Pierce Chemical Co. (1984), *supra*.

Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the art, as described generally in Sambrook et al., Molecular Cloning. A Laboratory Manual,

Cold Spring Harbor Press, Cold Spring Harbor, New York (1982), which is incorporated herein by reference. Thus, fusion proteins which comprise one or more peptide sequences of the invention can be used to present the appropriate T cell epitope.

As the coding sequence for peptides of the length contemplated herein can  
5 be synthesized by chemical techniques, for example, the phosphotriester method of  
Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981), modification can be made simply  
by substituting the appropriate base(s) for those encoding the native peptide sequence.  
The coding sequence can then be provided with appropriate linkers and ligated into  
expression vectors commonly available in the art, and the vectors used to transform  
10 suitable hosts to produce the desired fusion protein. A number of such vectors and  
suitable host systems are now available. For expression of the fusion proteins, the coding  
sequence will be provided with operably linked start and stop codons, promoter and  
terminator regions and usually a replication system to provide an expression vector for  
expression in the desired cellular host. For example, promoter sequences compatible with  
15 bacterial hosts are provided in plasmids containing convenient restriction sites for  
insertion of the desired coding sequence. The resulting expression vectors are  
transformed into suitable bacterial hosts. Of course, yeast or mammalian cell hosts may  
also be used, employing suitable vectors and control sequences.

The peptides of the present invention and pharmaceutical and vaccine  
20 compositions thereof are useful for administration to mammals, particularly humans, to  
treat and/or prevent viral infection and cancer. Examples of diseases which can be treated  
using the immunogenic peptides of the invention include prostate cancer, hepatitis B,  
hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV and  
condyloma acuminatum.

25 For pharmaceutical compositions, the immunogenic peptides of the  
invention are administered to an individual already suffering from cancer or infected with  
the virus of interest. Those in the incubation phase or the acute phase of infection can be  
treated with the immunogenic peptides separately or in conjunction with other treatments,  
as appropriate. In therapeutic applications, compositions are administered to a patient in  
30 an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and  
to cure or at least partially arrest symptoms and/or complications. An amount adequate to  
accomplish this is defined as "therapeutically effective dose." Amounts effective for this  
use will depend on, e.g., the peptide composition, the manner of administration, the stage

and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0  $\mu\text{g}$  to about 5000  $\mu\text{g}$  of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0  $\mu\text{g}$  to about 1000  $\mu\text{g}$  of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

For therapeutic use, administration should begin at the first sign of viral infection or the detection or surgical removal of tumors or shortly after diagnosis in the case of acute infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses followed by boosting doses may be required.

Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals. For those individuals susceptible (or predisposed) to developing chronic infection the compositions are particularly useful in methods for preventing the evolution from acute to chronic infection. Where the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.

The peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eliminate virus-infected cells in carriers. It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate a cytotoxic T cell response. Thus, for treatment of chronic infection, a representative dose is in the range of about 1.0  $\mu\text{g}$  to about 5000  $\mu\text{g}$ , preferably about 5  $\mu\text{g}$  to 1000  $\mu\text{g}$  for a 70 kg patient per dose. Immunizing doses followed by boosting doses at established intervals, e.g., from one to four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue

until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.

The pharmaceutical compositions for therapeutic treatment are intended for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of CTL stimulatory peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or targeted selectively to infected cells, as well as increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where

the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g.,

5 liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, incorporated herein by reference.

For targeting to the immune cells, a ligand to be incorporated into the

10 liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

15 For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as

20 those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant

25 must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute

30 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

In another aspect the present invention is directed to vaccines which contain as an active ingredient an immunogenically effective amount of an immunogenic peptide as described herein. The peptide(s) may be introduced into a host, including humans, linked to its own carrier or as a homopolymer or heteropolymer of active peptide units. Such a polymer has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the virus or tumor cells. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are materials well known in the art. And, as mentioned above, CTL responses can be primed by conjugating peptides of the invention to lipids, such as P3CSS. Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen, and the host becomes at least partially immune to later infection, or resistant to developing chronic infection.

Vaccine compositions containing the peptides of the invention are administered to a patient susceptible to or otherwise at risk of viral infection or cancer to elicit an immune response against the antigen and thus enhance the patient's own immune response capabilities. Such an amount is defined to be an "immunogenically effective dose." In this use, the precise amounts again depend on the patient's state of health and weight, the mode of administration, the nature of the formulation, etc., but generally range from about 1.0  $\mu$ g to about 5000  $\mu$ g per 70 kilogram patient, more commonly from about 10  $\mu$ g to about 500  $\mu$ g mg per 70 kg of body weight.

In some instances it may be desirable to combine the peptide vaccines of the invention with vaccines which induce neutralizing antibody responses to the virus of interest, particularly to viral envelope antigens.

For therapeutic or immunization purposes, nucleic acids encoding one or more of the peptides of the invention can also be administered to the patient. A number

of methods are conveniently used to deliver the nucleic acids to the patient. For instance, the nucleic acid can be delivered directly, as "naked DNA". This approach is described, for instance, in Wolff *et al.*, *Science* 247: 1465-1468 (1990) as well as U.S. Patent Nos. 5,580,859 and 5,589,466. The nucleic acids can also be administered using ballistic

5 delivery as described, for instance, in U.S. Patent No. 5,204,253. Particles comprised solely of DNA can be administered. Alternatively, DNA can be adhered to particles, such as gold particles. The nucleic acids can also be delivered complexed to cationic compounds, such as cationic lipids. Lipid-mediated gene delivery methods are described, for instance, in WO 96/18372; WO 93/24640; Mannino and Gould-Fogerite (1988)

10 *BioTechniques* 6(7): 682-691; Rose U.S. Pat No. 5,279,833; WO 91/06309; and Felgner *et al.* (1987) *Proc. Natl. Acad. Sci. USA* 84: 7413-7414. The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode the peptides of the invention. Upon introduction into an acutely or

15 chronically infected host or into a noninfected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits a host CTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No. 4,722,848, incorporated herein by reference. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover *et al.* (*Nature* 351:456-460

20 (1991)) which is incorporated herein by reference. A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g., Salmonella typhi vectors and the like, will be apparent to those skilled in the art from the description herein.

A preferred means of administering nucleic acids encoding the peptides of

25 the invention uses minigene constructs encoding multiple epitopes of the invention. To create a DNA sequence encoding the selected CTL epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes are reverse translated. A human codon usage table is used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences are directly adjoined, creating a continuous polypeptide

30 sequence. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequence that could be reverse translated and included in the minigene sequence include: helper T lymphocyte epitopes, a leader (signal) sequence, and an endoplasmic reticulum retention signal. In

addition, MHC presentation of CTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL epitopes.

The minigene sequence is converted to DNA by assembling  
 5 oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides are joined using T4 DNA ligase. This synthetic minigene, encoding the CTL epitope polypeptide, can then be cloned into a desired expression vector.

10 Standard regulatory sequences well known to those of skill in the art are included in the vector to ensure expression in the target cells. Several vector elements are required: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an *E. coli* origin of replication; and an *E. coli* selectable marker (e.g. ampicillin or kanamycin resistance).  
 15 Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene  
 20 expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences can also be considered for increasing minigene expression. It has recently been proposed that immunostimulatory sequences (ISSs or CpGs) play a role in the immunogenicity of DNA vaccines. These sequences could be included in the vector,  
 25 outside the minigene coding sequence, if found to enhance immunogenicity.

In some embodiments, a bioisotonic expression vector, to allow production of the minigene-encoded epitopes and a second protein included to enhance or decrease immunogenicity can be used. Examples of proteins or polypeptides that could  
 30 beneficially enhance the immune response if co-expressed include cytokines (e.g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e.g. LeIF) or costimulatory molecules. Helper (HTL) epitopes could be joined to intracellular targeting signals and expressed separately from the CTL epitopes. This would allow direction of the HTL epitopes to a cell compartment different than the CTL epitopes. If required, this could facilitate more

efficient entry of HTL epitopes into the MHC class II pathway, thereby improving CTL induction. In contrast to CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF- $\beta$ ) may be beneficial in certain diseases.

5                   Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis.

10       Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

                  Therapeutic quantities of plasmid DNA are produced by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate fermentation medium (such as Terrific Broth), and grown to saturation in shaker flasks or  
15       a bioreactor according to well known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by Quiagen. If required, supercoiled DNA can be isolated from the open circular and linear forms using gel electrophoresis or other methods.

                  Purified plasmid DNA can be prepared for injection using a variety of  
20       formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). A variety of methods have been described, and new techniques may become available. As noted above, nucleic acids are conveniently formulated with cationic lipids. In addition, glycolipids, fusogenic liposomes, peptides and compounds referred to collectively as protective, interactive, non-condensing (PINC)  
25       could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

                  Target cell sensitization can be used as a functional assay for expression and MHC class I presentation of minigene-encoded CTL epitopes. The plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL  
30       chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be co-transfected to allow enrichment of transfected cells using fluorescence activated cell

sorting (FACS). These cells are then chromium-51 labeled and used as target cells for epitope-specific CTL lines. Cytolysis, detected by  $^{51}\text{Cr}$  release, indicates production of MHC presentation of minigene-encoded CTL epitopes.

*In vivo* immunogenicity is a second approach for functional testing of minigene DNA formulations. Transgenic mice expressing appropriate human MHC molecules are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g. IM for DNA in PBS, IP for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for 1 week in the presence of peptides encoding each epitope being tested. These effector cells (CTLs) are assayed for cytolysis of peptide-loaded, chromium-51 labeled target cells using standard techniques. Lysis of target cells sensitized by MHC loading of peptides corresponding to minigene-encoded epitopes demonstrates DNA vaccine function for *in vivo* induction of CTLs.

Antigenic peptides may be used to elicit CTL ex vivo, as well. The resulting CTL, can be used to treat chronic infections (viral or bacterial) or tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a peptide vaccine approach of therapy. Ex vivo CTL responses to a particular pathogen (infectious agent or tumor antigen) are induced by incubating in tissue culture the patient's CTL precursor cells (CTLp) together with a source of antigen-presenting cells (APC) and the appropriate immunogenic peptide. After an appropriate incubation time (typically 1-4 weeks), in which the CTLp are activated and mature and expand into effector CTL, the cells are infused back into the patient, where they will destroy their specific target cell (an infected cell or a tumor cell).

The peptides may also find use as diagnostic reagents. For example, a peptide of the invention may be used to determine the susceptibility of a particular individual to a treatment regimen which employs the peptide or related peptides, and thus may be helpful in modifying an existing treatment protocol or in determining a prognosis for an affected individual. In addition, the peptides may also be used to predict which individuals will be at substantial risk for developing chronic infection.

The following example is offered by way of illustration, not by way of limitation.

## EXAMPLE 1

Class I antigen isolation was carried out as described in the related applications, noted above. Naturally processed peptides were then isolated and sequenced as described there. An allele-specific motif and algorithms were determined and quantitative binding assays were carried out.

Using the motifs identified above for the HLA-A2.1 allele amino acid sequences from a number of antigens were analyzed for the presence of these motifs. Table 3 provides the results of these searches. The letter "J" represents norleucine.

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

Table 3

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
17.0317	9	LQIGNIISI	Flu.24	0.0130
38.0103	9	NLSLSCHAA	CEA.432	0.0110
1233.11	9	YLSGANLNV	CEA.605V9	0.0690
1295.03	9	SMPPPGTRV	p53.149M2	0.0290
1295.04	9	SLPPPGTRV	p53.149L2	0.0410
1317.24	9	KTCPVQLWV	p53.139	0.0069
1323.02	9	KLLPENNVV	p53.24V9	0.0130
1323.04	9	ALNKMFBQV	p53.129B7V9	0.0260
1323.06	9	KLBPVQLWV	p53.139L2B3	0.1100
1323.08	9	BLTIHYNYV	p53.229B1L2V9	0.0430
1323.18	10	LLPPQHLIRV	p53.188L2	0.0061
1323.29	11	YMCNSSCMGGM	p53.236	0.0075
1323.31	11	YLCNSSCMGGV	p53.236L2V11	0.2300
1323.34	11	KLYQGSYGFRV	p53.101L2V11	0.0620
1324.07	9	CQLAKTCPV	p53.135	0.0240
1325.01	9	RLPEAAPPV	p53.65L2	0.0640
1325.02	9	GLAPPQHLV	p53.187V9	0.0130
1325.04	9	KMAELVHFL	MAGE3.112M2	0.2100

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
1325.05	9	KLAELVHFL	MAGE3.112L2	0.2500
1326.01	9	CLLAKTCPV	p53.135L2	0.0400
1326.02	9	KLSQHMTEV	p53.164L2	0.0410
1326.04	9	ELAPVVAPV	p53.68L2V9	0.0860
1326.06	10	QLAKTCPVQV	p53.136	0.0320
1326.08	9	HLTEVVRRV	p53.168L2	0.0180
1329.01	11	KTYQGSYGFR		0.0028
1329.03	10	VVVPEPEPV	p53.216	0.0081
1329.14	9	BQLAKTBPV	p53.135B1B7	0.0490
1329.15	9	BLLAKTBPV	p53.135B1L2B7	0.1100
1330.01	9	QIIGYVIGT	CEA.78	0.0160
1330.02	9	QLIGYVIGV	CEA.78L2V9	0.5300
1330.05	9	YVCGIQNSV	CEA.569	0.0510
1330.06	9	YLCGIQNSV	CEA.569L2	0.1000
1330.07	9	ATVGIMIGV	CEA.687	0.1400
1330.08	9	ALVGIMIGV	CEA.687L2	0.5000
1330.09	10	VLYGPDDPTI	CEA.411	0.0170
1330.10	10	VLYGPDDPTV	CEA.411V10	0.0310
1331.02	9	DLMLSPDDV	p53.42V9	
1331.03	9	ALMLSPDDI	p53.42A1	
1331.04	9	ALMLSPDDV	p53.42A1V9	
1331.05	9	DLMLSPADI	p53.42A7	
1331.06	9	DLMLSPADV	p53.42A7V9	
1331.07	9	DLMLSPDAI	p53.42A8	
1331.08	9	DLMLSPDAV	p53.42A8V9	
38.0007	9	AILTFGSFV	KSHV.89	0.0850
38.0009	9	HLRDFALAV	KSHV.106	0.0183
38.0015	9	ALLGSIAL	KSHV.155	0.0470
38.0018	9	ALLATILAA	KSHV.161	0.0490
38.0019	9	LLATILAAV	KSHV.162	0.1600
38.0022	9	RLFADELAA	KSHV.14	0.0150

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
38.0024	9	YLSKCTLAV	KSHV.65	0.2000
38.0026	9	LVYHIYSKI	KSHV.153	0.0457
38.0029	9	SMYLCILSA	KSHV.208	0.0250
38.0030	9	YLCILSALV	KSHV.210	0.3500
38.0033	9	VMFSYLQSL	KSHV.268	0.5000
38.0035	9	RLHVVYAYSA	KSHV.285	0.0270
38.0039	9	GLQTLGAFV	KSHV.98	0.0110
38.0040	9	FVEEQMTWA	KSHV.105	0.0380
38.0041	9	QMTWAQTVV	KSHV.109	0.0110
38.0042	9	IILDTAIFV	KSHV.130	0.6800
38.0043	9	AIFVCNAFV	KSHV.135	0.0910
38.0046	9	AMGNRLVEA	KSHV.172	0.0200
38.0047	9	RLVEACNLL	KSHV.176	0.0180
38.0059	9	TLSIVTFSL	KSHV.198	0.2200
38.0063	9	KLSVLLLEV	KSHV.292	0.1400
38.0064	9	LLLEVNRSV	KSHV.296	0.0270
38.0068	9	FVSSPTLPV	KSHV.78	0.0350
38.0070	9	AMLVLLAEI	KSHV.281	0.0820
38.0075	9	QMARLAWEA	KSHV.1116	0.0990
38.0131	10	VLAIEGIFMA	KSHV.10	0.0730
38.0132	10	YLYHPLLSP	KSHV.27	0.1400
38.0134	10	SLFEAMLANV	KSHV.49	0.9500
38.0135	10	STTGINQLGL	KSHV.62	0.0710
38.0137	10	LAILTFGSFV	KSHV.88	0.0160
38.0139	10	ALLGSIALLA	KSHV.155	0.0360
38.0141	10	ALLATILAAV	KSHV.161	0.1100
38.0142	10	LLATILAAVA	KSHV.162	0.0110
38.0143	10	RLFADELAAL	KSHV.14	0.1800
38.0148	10	YLSKCTLAVL	KSHV.65	0.0300
38.0150	10	LLVYHIYSKI	KSHV.152	0.0130
38.0151	10	SMYLCILSAL	KSHV.208	0.0360

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
38.0153	10	HLHRQMLSFV	KSHV.68	0.0160
38.0163	10	LLCGKTGAFL	KSHV.167	0.0100
38.0164	10	ETLSIVTFSL	KSHV.197	0.0180
39.0063	9	VMCTYSPPL	mp53.119	1.4000
39.0065	9	KLFCQLAKT	mp53.129	0.0160
39.0067	9	ATPPAGSRV	mp53.146	0.0130
39.0133	10	FLQSGTAKSV	mp53.110	0.0180
39.0169	10	CMDRGLTVFV	KSHV.311	0.0120
39.0170	10	VLLNWWRWRL	KSHV.327	0.1500
40.0070	9	GVFTGLTHI	HCV.1565	0.0110
40.0072	9	QMWKCLIRL	HCV.1611	0.0620
40.0074	9	IMTCMSADL	HCV.1650	0.0121
40.0076	9	ALAAAYCLST	HCV.1674	0.2500
40.0080	9	VLSGKPAII	HCV.1692	0.0150
40.0082	9	FISGIQYLA	HCV.1773	0.1000
40.0134	10	YIMTCMSADL	HCV.1649	0.0300
40.0137	10	AIASLMAFTA	HCV.1791	0.0580
40.0138	10	GLAGAAIGSV	HCV.1838	0.0320
41.0058	8	MIGVLVGV	CEA.692	0.0120
41.0061	9	VLPLAYISL	TRP1	0.0110
41.0062	9	SLGCIFFPL	TRP1	0.9700
41.0063	9	PLAYISLFL	TRP1	0.0220
41.0065	9	LMLFYQVWA	TRP1	0.0270
41.0071	9	NISIYNYFV	TRP1	0.2300
41.0072	9	NISVYNYFV	TRP1	0.0600
41.0075	9	FVWTHYYSV	TRP1	1.5000
41.0077	9	FLTWHRYHL	TRP1	0.5500
41.0078	9	LTWHRYHLL	TRP1	0.1600
41.0082	9	MLQEPSFSL	TRP1	0.6900
41.0083	9	SLPYWNFAT	TRP1	0.0110
41.0088	9	RLPEPQDVA	TRP1	0.0180

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
41.0090	9	VTQCLEVRV	TRP1	0.0160
41.0096	9	LLHTFTDAV	TRP1	0.2700
41.0100	9	NMVPFWPPV	TRP1	0.6200
41.0104	9	AVVGALLLV	TRP1	0.0210
41.0105	9	AVVAALLLV	TRP1	0.0390
41.0108	9	LLVAAIFGV	TRP1	1.9000
41.0112	9	SMDEANQPL	TRP1	0.0770
41.0114	9	VLPLAYISV	TRP1	0.1100
41.0115	9	SLGCIFFPV	TRP1	3.2000
41.0116	9	PLAYISLFV	TRP1	0.0310
41.0117	9	LLLFQQARV	TRP1	0.1100
41.0118	9	LMLFYQVWV	TRP1	2.4000
41.0119	9	LLPSSGPGV	TRP1	0.3700
41.0121	9	NLSIYNYFV	TRP1	0.9700
41.0122	9	NLSVYNYFV	TRP1	0.8700
41.0123	9	FLWTHYYSV	TRP1	5.6000
41.0124	9	SLKKTFLGV	TRP1	0.0224
41.0125	9	FLTWHRYHV	TRP1	0.3800
41.0129	9	MLQEPSFSV	TRP1	1.6000
41.0130	9	SLPYWNFAV	TRP1	0.5700
41.0131	9	ALGKNVCDV	TRP1	0.0160
41.0132	9	SLLISPNSV	TRP1	0.1300
41.0133	9	SLFSQWRVV	TRP1	0.0740
41.0134	9	TLGTLCNSV	TRP1	0.0330
41.0136	9	RLPEPQDVV	TRP1	0.1000
41.0137	9	VLQCLEVRV	TRP1	0.0360
41.0138	9	SLNSFRNTV	TRP1	0.0140
41.0139	9	SLDSFRNTV	TRP1	0.0440
41.0141	9	FLNGTGGQV	TRP1	0.0220
41.0142	9	VLLHTFTDV	TRP1	0.0180
41.0145	9	ALVGALLLV	TRP1	0.2600

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	A*0201
41.0146	9	ALVAALLLV	TRP1	0.5800
41.0147	9	LLVALIFGV	TRP1	1.0000
41.0148	9	YLIRARRSV	TRP1	0.0170
41.0149	9	SMDEANQPV	TRP1	0.1600
41.0151	10	SLGCIFFPLL	TRP1	0.1800
41.0157	10	GMCCPDLSPV	TRP1	0.0950
41.0160	10	AACNQKILTV	TRP1	0.0120
41.0162	10	FLTWHRYHLL	TRP1	0.0830
41.0166	10	SLHNLAHLFL	TRP1	0.3900
41.0174	10	LLLVAAIFGV	TRP1	0.3000
41.0177	10	LLVAAIFGVA	TRP1	0.0820
41.0178	10	ALIFGTASYL	TRP1	0.0230
41.0180	10	SMDEANQPLL	TRP1	0.0250
41.0181	10	LLTDQYQCYA	TRP1	0.0320
41.0183	10	SLGCIFFPLV	TRP1	0.3200
41.0186	10	FLMLFYQVWV	TRP1	0.8100
41.0189	10	ALCDQRVLIV	TRP1	0.0530
41.0190	10	ALCNQKILTV	TRP1	0.0770
41.0191	10	FLTWHRYHLV	TRP1	0.0510
41.0197	10	SLHNLAHLFV	TRP1	0.5000
41.0198	10	NLAHLFLNGV	TRP1	0.4100
41.0199	10	NMVPFWPPVV	TRP1	0.2800
41.0201	10	ILVVAALLLV	TRP1	0.0190
41.0203	10	LLVALIFGTV	TRP1	0.1200
41.0205	10	ALIFGTASYV	TRP1	0.0900
41.0206	10	SMDEANQPLV	TRP1	0.0350
41.0207	10	LLTDQYQCYV	TRP1	0.2100
41.0212	11	LLIQNIQNDT	CEA.107	0.0140
41.0214	11	IIQNDTGfYTL	CEA.112	0.0130
41.0221	11	TLFNVTRNDTA	CEA.201	0.0110
41.0235	11	LTLFSVTRNDV	CEA.378	0.0150

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	<u>A*0201</u>
41.0243	11	GLYTCQANNSA	CEA.473	0.0290
41.0268	11	ATVGIMIGVLV	CEA.687	0.0160
44.0075	11	GLVPPQHLIRV	mp53.184.V3	0.0370
44.0087	11	GLAPPVHLIRV	mp53.184.V6	0.0330
44.0092	11	GLAPPEHLIRV	mp53.184.E6	0.1600
1227.10	9	ILIGVLVGV	CEA.691.L2	0.2300
1234.26	10	YLIMVKCWMV	Her2/neu.952.L2	0.3800
			V10	
1295.06	9	LLGRDSFEV	mp53.261	0.2000
1319.01	9	FMYSDFHFI	Flu.RRP2.446	0.4400
1319.06	9	NMLSTVLGV	Flu.RRP2.446	0.1700
1319.14	9	SLENFRAYV	Flu.RRP2.446	0.0430
1325.06		KMAELVHFV	Mage3.112	0.1900
1325.07		KLAELVHFV	Mage3.112	0.3500
1334.01		VLIQRNPQV	Her2/neu.153.V9	0.0910
1334.02		VLLGVVFGV	Her2/neu.665.L2	2.1000
			V9	
1334.03		SLISAVVGV	Her2/neu.653.L2	0.7000
			V9	
1334.04		YMIMVKBWMI	Her2/neu.952.B7	0.2700
1334.05		YLIMVKBWMV	Her2/neu.952.L2	0.6900
			B7V10	
1334.06		KLWEELSVV	Mage3.220.L2V	0.4500
			9	
1334.08		AMBRWGLLV	Her2/neu.5.M2B	0.1400
			3V9	
1345.01	9	IIGVLVGV	CEA.691.J2	0.0570
1345.02	9	ATVGIIIGV	CEA.687.J6	0.1595
1345.03	9	SJPPPGTRV	p53.149.J2	0.0545
1345.04	10	LVFGIELJEV	MAGE3.160.J8	0.7650
918.12	8	ILGFVFTL	Flu.M1.59	0.7900

<u>Peptide</u>	<u>AA</u>	<u>Sequence</u>	<u>Source</u>	A*0201
1095.22	9	KIFGSLAFL	Her2/neu	
1090.01	10	YLQLVFGIEV	MAGE2	
1126.01	9	MMNDQLMFL	PSM	
1126.02	10	ALVLAGGFFL	PSM	
1126.03	9	WLCAGALVL	PSM	
1126.05	9	MVFELANSI	PSM	
1126.06	10	RMMNDQLMFL	PSM	
1126.09	9	LVLAGGFFL	PSM	
1126.10	9	VLAGGFFLL	PSM	
1126.12	9	LLHETDSAV	PSM	
1126.14	9	LMYSLVHNL	PSM	
1126.16	10	QLMFLERAFL	PSM	
1126.17	9	LMFLERAFL	PSM	
1126.20	10	KLGSGNDFEV	PSM	
1129.01	10	LLQERGVAYI	PSM	
1129.04	10	GMPEGDLVYV	PSM	
1129.05	10	FLDELKAENI	PSM	
1129.08	9	ALFDIESKV	PSM	
1129.10	10	GLPSIPVHPI	PSM	

## II. Non-HLA-A2 Motifs

The present invention also relates to the determination of allele-specific peptide motifs for human Class I MHC (sometimes referred to as HLA) allele subtypes.

- 5 These motifs are then used to define T cell epitopes from any desired antigen, particularly those associated with human viral diseases, cancers or autoimmune diseases, for which the amino acid sequence of the potential antigen or autoantigen targets is known.

- Epitopes on a number of potential target proteins can be identified in this manner. Examples of suitable antigens include prostate specific antigen (PSA), hepatitis
- 10 B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens and human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, and Her2/neu.

Peptides comprising the epitopes from these antigens are synthesized and then tested for their ability to bind to the appropriate MHC molecules in assays using, for example, purified class I molecules and radioiodinated peptides and/or cells expressing empty class I molecules by, for instance, immunofluorescent staining and flow microfluorimetry, peptide-dependent class I assembly assays, and inhibition of CTL recognition by peptide competition. Those peptides that bind to the class I molecule are further evaluated for their ability to serve as targets for CTLs derived from infected or immunized individuals, as well as for their capacity to induce primary in vitro or in vivo CTL responses that can give rise to CTL populations capable of reacting with virally infected target cells or tumor cells as potential therapeutic agents.

The MHC class I antigens are encoded by the HLA-A, B, and C loci. HLA-A and B antigens are expressed at the cell surface at approximately equal densities, whereas the expression of HLA-C is significantly lower (perhaps as much as 10-fold lower). Each of these loci have a number of alleles. The peptide binding motifs of the invention are relatively specific for each allelic subtype.

For peptide-based vaccines, the peptides of the present invention preferably comprise a motif recognized by an MHC I molecule having a wide distribution in the human population. Since the MHC alleles occur at different frequencies within different ethnic groups and races, the choice of target MHC allele may depend upon the target population. Table 4 shows the frequency of various alleles at the HLA-A locus products among different races. For instance, the majority of the Caucasoid population can be covered by peptides which bind to four HLA-A allele subtypes, specifically HLA-A2.1, A1, A3.2, and A24.1. Similarly, the majority of the Asian population is encompassed with the addition of peptides binding to a fifth allele HLA-A11.2.

TABLE 4

<u>A Allele/Subtype</u>	<u>N(69)*</u>	<u>A(54)</u>	<u>C(502)</u>
A1	10.1(7)	1.8(1)	27.4(138)
A2.1	11.5(8)	37.0(20)	39.8(199)
A2.2	10.1(7)	0	3.3(17)

A2.3	1.4(1)	5.5(3)	0.8(4)
A2.4	-	-	-
A2.5	-	-	-
A3.1	1.4(1)	0	0.2(0)
A3.2	5.7(4)	5.5(3)	21.5(108)
A11.1	0	5.5(3)	0
A11.2	5.7(4)	31.4(17)	8.7(44)
A11.3	0	3.7(2)	0
A23	4.3(3)	-	3.9(20)
A24	2.9(2)	27.7(15)	15.3(77)
A24.2	-	-	-
A24.3	-	-	-
A25	1.4(1)	-	6.9(35)
A26.1	4.3(3)	9.2(5)	5.9(30)
A26.2	7.2(5)	-	1.0(5)
A26V	-	3.7(2)	-
A28.1	10.1(7)	-	1.6(8)
A28.2	1.4(1)	-	7.5(38)
A29.1	1.4(1)	-	1.4(7)
A29.2	10.1(7)	1.8(1)	5.3(27)
A30.1	8.6(6)	-	4.9(25)
A30.2	1.4(1)	-	0.2(1)
A30.3	7.2(5)	-	3.9(20)
A31	4.3(3)	7.4(4)	6.9(35)
A32	2.8(2)	-	7.1(36)
Aw33.1	8.6(6)	-	2.5(13)
Aw33.2	2.8(2)	16.6(9)	1.2(6)
Aw34.1	1.4(1)	-	-
Aw34.2	14.5(10)	-	0.8(4)
Aw36	5.9(4)	-	-

Table compiled from B. DuPont, Immunobiology of HLA, Vol. I, Histocompatibility Testing 1987, Springer-Verlag, New York 1989.

\* N - negroid; A = Asian; C = Caucasoid. Numbers in parenthesis represent the number of individuals included in the analysis.

5                   The nomenclature used to describe peptide compounds follows the conventional practice wherein the amino group is presented to the left (the N-terminus) and the carboxyl group to the right (the C-terminus) of each amino acid residue. In the formulae representing selected specific embodiments of the present invention, the amino- and carboxyl-terminal groups, although not specifically shown, are in the form they  
10 would assume at physiologic pH values, unless otherwise specified. In the amino acid structure formulae, each residue is generally represented by standard three letter or single letter designations. The L-form of an amino acid residue is represented by a capital single letter or a capital first letter of a three-letter symbol, and the D-form for those amino acids is represented by a lower case single letter or a lower case three letter symbol. Glycine  
15 has no asymmetric carbon atom and is simply referred to as "Gly" or G.

                  The procedures used to identify peptides of the present invention generally follow the methods disclosed in Falk et al., Nature 351:290 (1991), which is incorporated herein by reference. Briefly, the methods involve large-scale isolation of MHC class I molecules, typically by immunoprecipitation or affinity chromatography, from the  
20 appropriate cell or cell line. Examples of other methods for isolation of the desired MHC molecule equally well known to the artisan include ion exchange chromatography, lectin chromatography, size exclusion, high performance ligand chromatography, and a combination of all of the above techniques.

                  A large number of cells with defined MHC molecules, particularly MHC  
25 Class I molecules, are known and readily available. For example, human EBV-transformed B cell lines have been shown to be excellent sources for the preparative isolation of class I and class II MHC molecules. Well-characterized cell lines are available from private and commercial sources, such as American Type Culture Collection ("Catalogue of Cell Lines and Hybridomas," 6th edition (1988) Rockville,  
30 Maryland, U.S.A.); National Institute of General Medical Sciences 1990/1991 Catalog of Cell Lines (NIGMS) Human Genetic Mutant Cell Repository, Camden, NJ; and ASHI Repository, Bingham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Table 5 lists some B cell lines suitable for use as sources for HLA-A alleles. All of these cell lines can be grown in large batches and are therefore useful for large scale production

of MHC molecules. One of skill will recognize that these are merely exemplary cell lines and that many other cell sources can be employed. Similar EBV B cell lines homozygous for HLA-B and HLA-C could serve as sources for HLA-B and HLA-C alleles, respectively.

5

TABLE 5

## HUMAN CELL LINES (HLA-A SOURCES)

HLA-A allele	B cell line
A1	MAT COX (9022) STEINLIN (9087)
A2.1	JY
A3.2	EHM (9080) HO301 (9055)GM3107
A24.1	T3(9107),TISI (9042)
A11	BVR (GM6828A) WT100 (GM8602)WT52 (GM8603)

In the typical case, immunoprecipitation is used to isolate the desired allele. A number of protocols can be used, depending upon the specificity of the antibodies used. For example, allele-specific mAb reagents can be used for the affinity purification of the HLA-A, HLA-B, and HLA-C molecules. Several mAb reagents for the isolation of HLA-A molecules are available (Table 6). Thus, for each of the targeted HLA-A alleles, reagents are available that may be used for the direct isolation of the HLA-A molecules. Affinity columns prepared with these mAbs using standard techniques are successfully used to purify the respective HLA-A allele products.

15

In addition to allele-specific mAbs, broadly reactive anti-HLA-A, B, C mAbs, such as W6/32 and B9.12.1, and one anti-HLA-B, C mAb, B1.23.2, could be used in alternative affinity purification protocols as described in the example section below.

TABLE 6

## ANTIBODY REAGENTS

anti-HLA	Name	
HLA-A1	12/18	
HLA-A3	GAPA3	(ATCC, HB122)
HLA-11,24.1	A11.1M	(ATCC, HB164)
HLA-A,B,C	W6/32	(ATCC, HB95)
monomorphic	B9.12.1	(INSERM-CNRS)
HLA-B,C	B.1.23.2	(INSERM-CNRS)
monomorphic		

5                   The peptides bound to the peptide binding groove of the isolated MHC molecules are eluted typically using acid treatment. Peptides can also be dissociated from class I molecules by a variety of standard denaturing means, such as heat, pH, detergents, salts, chaotropic agents, or a combination thereof.

10                   Peptide fractions are further separated from the MHC molecules by reversed-phase high performance liquid chromatography (HPLC) and sequenced. Peptides can be separated by a variety of other standard means well known to the artisan, including filtration, ultrafiltration, electrophoresis, size chromatography, precipitation with specific antibodies, ion exchange chromatography, isoelectrofocusing, and the like.

15                   Sequencing of the isolated peptides can be performed according to standard techniques such as Edman degradation (Hunkapiller, M.W., et al., Methods Enzymol. 91, 399 [1983]). Other methods suitable for sequencing include mass spectrometry sequencing of individual peptides as previously described (Hunt, et al., Science 225:1261 (1992), which is incorporated herein by reference). Amino acid sequencing of bulk heterogenous peptides (e.g., pooled HPLC fractions) from different  
20                   class I molecules typically reveals a characteristic sequence motif for each class I allele.

                  Definition of motifs specific for different class I alleles allows the identification of potential peptide epitopes from an antigenic protein whose amino acid sequence is known. Typically, identification of potential peptide epitopes is initially

carried out using a computer to scan the amino acid sequence of a desired antigen for the presence of motifs. The epitopic sequences are then synthesized. The capacity to bind MHC Class molecules is measured in a variety of different ways. One means is a Class I molecule binding assay as described in the related applications, noted above. Other

5 alternatives described in the literature include inhibition of antigen presentation (Sette, et al., J. Immunol. 141:3893 (1991), in vitro assembly assays (Townsend, et al., Cell 62:285 (1990), and FACS based assays using mutated cells, such as RMA.S (Melief, et al., Eur. J. Immunol. 21:2963 (1991)).

Next, peptides that test positive in the MHC class I binding assay are

10 assayed for the ability of the peptides to induce specific CTL responses in vitro. For instance, Antigen-presenting cells that have been incubated with a peptide can be assayed for the ability to induce CTL responses in responder cell populations. Antigen-presenting cells can be normal cells such as peripheral blood mononuclear cells or dendritic cells (Inaba, et al., J. Exp. Med. 166:182 (1987); Boog, Eur. J. Immunol. 18:219 [1988]).

15 Alternatively, mutant mammalian cell lines that are deficient in their ability to load class I molecules with internally processed peptides, such as the mouse cell lines RMA-S (Kärre, et al., Nature, 319:675 (1986); Ljunggren, et al., Eur. J. Immunol. 21:2963-2970 (1991)), and the human somatic T cell hybrid, T-2 (Cerundolo, et al., Nature 345:449-452 (1990)) and which have been transfected with the appropriate human

20 class I genes are conveniently used, when peptide is added to them, to test for the capacity of the peptide to induce in vitro primary CTL responses. Other eukaryotic cell lines which could be used include various insect cell lines such as mosquito larvae (ATCC cell lines CCL 125, 126, 1660, 1591, 6585, 6586), silkworm (ATTC CRL 8851), armyworm (ATCC CRL 1711), moth (ATCC CCL 80) and Drosophila cell lines such as a Schneider

25 cell line (see Schneider J. Embryol. Exp. Morphol. 27:353-365 [1927]).

Peripheral blood lymphocytes are conveniently isolated following simple venipuncture or leukapheresis of normal donors or patients and used as the responder cell sources of CTL precursors. In one embodiment, the appropriate antigen-presenting cells are incubated with 10-100  $\mu$ M of peptide in serum-free media for 4 hours under

30 appropriate culture conditions. The peptide-loaded antigen-presenting cells are then incubated with the responder cell populations in vitro for 7 to 10 days under optimized culture conditions. Positive CTL activation can be determined by assaying the cultures for the presence of CTLs that kill radiolabeled target cells, both specific peptide-pulsed

targets as well as target cells expressing endogenously processed form of the relevant virus or tumor antigen from which the peptide sequence was derived.

Specificity and MHC restriction of the CTL is determined by testing against different peptide target cells expressing appropriate or inappropriate human MHC class I. The peptides that test positive in the MHC binding assays and give rise to specific CTL responses are referred to herein as immunogenic peptides.

The immunogenic peptides can be prepared synthetically, or by recombinant DNA technology or from natural sources such as whole viruses or tumors. Although the peptide will preferably be substantially free of other naturally occurring host cell proteins and fragments thereof, in some embodiments the peptides can be synthetically conjugated to native fragments or particles.

The polypeptides or peptides can be a variety of lengths, either in their neutral (uncharged) forms or in forms which are salts, and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications, subject to the condition that the modification not destroy the biological activity of the polypeptides as herein described.

Desirably, the peptide will be as small as possible while still maintaining substantially all of the biological activity of the large peptide. When possible, it may be desirable to optimize peptides of the invention to a length of 9 or 10 amino acid residues, commensurate in size with endogenously processed viral peptides or tumor cell peptides that are bound to MHC class I molecules on the cell surface.

Peptides having the desired activity may be modified as necessary to provide certain desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide to bind the desired MHC molecule and activate the appropriate T cell. For instance, the peptides may be subject to various changes, such as substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use, such as improved MHC binding. By conservative substitutions is meant replacing an amino acid residue with another which is biologically and/or chemically similar, e.g., one hydrophobic residue for another, or one polar residue for another. The substitutions include combinations such as Gly, Ala; Val, Ile, Leu, Met; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr. The effect of single amino acid substitutions may also be probed using D-amino acids. Such modifications may be made

using well known peptide synthesis procedures, as described in e.g., Merrifield, Science 232:341-347 (1986), Barany and Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp. 1-284 (1979); and Stewart and Young, Solid Phase Peptide Synthesis, (Rockford, Ill., Pierce), 2d Ed. (1984), incorporated by reference herein.

5           The peptides can also be modified by extending or decreasing the compound's amino acid sequence, e.g., by the addition or deletion of amino acids. The peptides or analogs of the invention can also be modified by altering the order or composition of certain residues, it being readily appreciated that certain amino acid residues essential for biological activity, e.g., those at critical contact sites or conserved  
10 residues, may generally not be altered without an adverse effect on biological activity. The non-critical amino acids need not be limited to those naturally occurring in proteins, such as L- $\alpha$ -amino acids, or their D-isomers, but may include non-natural amino acids as well, such as  $\beta$ - $\gamma$ - $\delta$ -amino acids, as well as many derivatives of L- $\alpha$ -amino acids.

Typically, a series of peptides with single amino acid substitutions are  
15 employed to determine the effect of electrostatic charge, hydrophobicity, etc. on binding. For instance, a series of positively charged (e.g., Lys or Arg) or negatively charged (e.g., Glu) amino acid substitutions are made along the length of the peptide revealing different patterns of sensitivity towards various MHC molecules and T cell receptors. In addition, multiple substitutions using small, relatively neutral moieties such as Ala, Gly, Pro, or  
20 similar residues may be employed. The substitutions may be homo-oligomers or hetero-oligomers. The number and types of residues which are substituted or added depend on the spacing necessary between essential contact points and certain functional attributes which are sought (e.g., hydrophobicity versus hydrophilicity). Increased binding affinity for an MHC molecule or T cell receptor may also be achieved by such substitutions,  
25 compared to the affinity of the parent peptide. In any event, such substitutions should employ amino acid residues or other molecular fragments chosen to avoid, for example, steric and charge interference which might disrupt binding.

Amino acid substitutions are typically of single residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final  
30 peptide. Substitutional variants are those in which at least one residue of a peptide has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 2 when it is desired to finely modulate the characteristics of the peptide.

TABLE 2

<u>Original Residue</u>	<u>Exemplary Substitution</u>
Ala	Ser
Arg	Lys, His
Asn	Gln
Asp	Glu
Cys	Ser
Glu	Asp
Gly	Pro
His	Lys; Arg
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg; His
Met	Leu; Ile
Phe	Tyr; Trp
Ser	Thr
Thr	Ser
Trp	Tyr; Phe
Tyr	Trp; Phe
Val	Ile; Leu
Pro	Gly

Substantial changes in function (e.g., affinity for MHC molecules or T cell receptors) are made by selecting substitutions that are less conservative than those in Table 2, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the structure of the peptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in peptide properties will be those in which (a) hydrophilic residue, e.g. seryl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a residue having an electropositive side chain, e.g., lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g.

glutamyl or aspartyl; or (c) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine.

The peptides may also comprise isosteres of two or more residues in the immunogenic peptide. An isostere as defined here is a sequence of two or more residues that can be substituted for a second sequence because the steric conformation of the first sequence fits a binding site specific for the second sequence. The term specifically includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the  $\alpha$ -carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone crosslinks.

See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, peptides and Proteins, Vol. VII (Weinstein ed., 1983).

Modifications of peptides with various amino acid mimetics or unnatural amino acids are particularly useful in increasing the stability of the peptide in vivo. Stability can be assayed in a number of ways. For instance, peptidases and various biological media, such as human plasma and serum, have been used to test stability. See, e.g., Verhoef et al., Eur. J. Drug Metab. Pharmacokin. 11:291-302 (1986). Half life of the peptides of the present invention is conveniently determined using a 25% human serum (v/v) assay. The protocol is generally as follows. Pooled human serum (Type AB, non-heat inactivated) is delipidated by centrifugation before use. The serum is then diluted to 25% with RPMI tissue culture media and used to test peptide stability. At predetermined time intervals a small amount of reaction solution is removed and added to either 6% aqueous trichloroacetic acid or ethanol. The cloudy reaction sample is cooled (4°C) for 15 minutes and then spun to pellet the precipitated serum proteins. The presence of the peptides is then determined by reversed-phase HPLC using stability-specific chromatography conditions.

The peptides of the present invention or analogs thereof which have CTL stimulating activity may be modified to provide desired attributes other than improved serum half life. For instance, the ability of the peptides to induce CTL activity can be enhanced by linkage to a sequence which contains at least one epitope that is capable of inducing a T helper cell response. Particularly preferred immunogenic peptides/T helper conjugates are linked by a spacer molecule. The spacer is typically comprised of relatively small, neutral molecules, such as amino acids or amino acid mimetics, which are substantially uncharged under physiological conditions. The spacers are typically

selected from, e.g., Ala, Gly, or other neutral spacers of nonpolar amino acids or neutral polar amino acids. It will be understood that the optionally present spacer need not be comprised of the same residues and thus may be a hetero- or homo-oligomer. When present, the spacer will usually be at least one or two residues, more usually three to six residues. Alternatively, the CTL peptide may be linked to the T helper peptide without a spacer.

The immunogenic peptide may be linked to the T helper peptide either directly or via a spacer either at the amino or carboxy terminus of the CTL peptide. The amino terminus of either the immunogenic peptide or the T helper peptide may be acylated. Exemplary T helper peptides include tetanus toxoid 830-843, influenza 307-319, malaria circumsporozoite 382-398 and 378-389.

In some embodiments it may be desirable to include in the pharmaceutical compositions of the invention at least one component which primes CTL. Lipids have been identified as agents capable of priming CTL in vivo against viral antigens. For example, palmitic acid residues can be attached to the alpha and epsilon amino groups of a Lys residue and then linked, e.g., via one or more linking residues such as Gly, Gly-Gly-, Ser, Ser-Ser, or the like, to an immunogenic peptide. The lipidated peptide can then be injected directly in a micellar form, incorporated into a liposome or emulsified in an adjuvant, e.g., incomplete Freund's adjuvant. In a preferred embodiment a particularly effective immunogen comprises palmitic acid attached to alpha and epsilon amino groups of Lys, which is attached via linkage, e.g., Ser-Ser, to the amino terminus of the immunogenic peptide.

As another example of lipid priming of CTL responses, *E. coli* lipoproteins, such as tripalmitoyl-S-glycerylcysteinylserine (P3CSS) can be used to prime virus specific CTL when covalently attached to an appropriate peptide. See, Deres et al., *Nature* 342:561-564 (1989), incorporated herein by reference. Peptides of the invention can be coupled to P<sup>3</sup>CSS, for example, and the lipopeptide administered to an individual to specifically prime a CTL response to the target antigen. Further, as the induction of neutralizing antibodies can also be primed with P<sup>3</sup>CSS conjugated to a peptide which displays an appropriate epitope, the two compositions can be combined to more effectively elicit both humoral and cell-mediated responses to infection.

In addition, additional amino acids can be added to the termini of a peptide to provide for ease of linking peptides one to another, for coupling to a carrier support, or

larger peptide, for modifying the physical or chemical properties of the peptide or oligopeptide, or the like. Amino acids such as tyrosine, cysteine, lysine, glutamic or aspartic acid, or the like, can be introduced at the C- or N-terminus of the peptide or oligopeptide. Modification at the C terminus in some cases may alter binding

5 characteristics of the peptide. In addition, the peptide or oligopeptide sequences can differ from the natural sequence by being modified by terminal-NH<sub>2</sub>-acylation, e.g., by alkanoyl (C<sub>1</sub>-C<sub>20</sub>) or thioglycolyl acetylation, terminal-carboxyl amidation, e.g., ammonia, methylamine, etc. In some instances these modifications may provide sites for linking to a support or other molecule.

10 The peptides of the invention can be prepared in a wide variety of ways. Because of their relatively short size, the peptides can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automatic synthesizers are commercially available and can be used in accordance with known protocols. See, for example, Stewart and Young, Solid Phase Peptide Synthesis, 2d. ed.,

15 Pierce Chemical Co. (1984), supra.

Alternatively, recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell and cultivated under conditions suitable for expression. These procedures are generally known in the

20 art, as described generally in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York (1982), which is incorporated herein by reference. Thus, fusion proteins which comprise one or more peptide sequences of the invention can be used to present the appropriate T cell epitope.

As the coding sequence for peptides of the length contemplated herein can

25 be synthesized by chemical techniques, for example, the phosphotriester method of Matteucci et al., J. Am. Chem. Soc. 103:3185 (1981), modification can be made simply by substituting the appropriate base(s) for those encoding the native peptide sequence. The coding sequence can then be provided with appropriate linkers and ligated into expression vectors commonly available in the art, and the vectors used to transform

30 suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are now available. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions and usually a replication system to provide an expression vector for

expression in the desired cellular host. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast or mammalian cell hosts may also be used, employing suitable vectors and control sequences.

The peptides of the present invention and pharmaceutical and vaccine compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent viral infection and cancer. Examples of diseases which can be treated using the immunogenic peptides of the invention include prostate cancer, hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV and condyloma acuminatum.

For pharmaceutical compositions, the immunogenic peptides of the invention are administered to an individual already suffering from cancer or infected with the virus of interest. Those in the incubation phase or the acute phase of infection can be treated with the immunogenic peptides separately or in conjunction with other treatments, as appropriate. In therapeutic applications, compositions are administered to a patient in an amount sufficient to elicit an effective CTL response to the virus or tumor antigen and to cure or at least partially arrest symptoms and/or complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgment of the prescribing physician, but generally range for the initial immunization (that is for therapeutic or prophylactic administration) from about 1.0  $\mu\text{g}$  to about 5000  $\mu\text{g}$  of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0  $\mu\text{g}$  to about 1000  $\mu\text{g}$  of peptide pursuant to a boosting regimen over weeks to months depending upon the patient's response and condition by measuring specific CTL activity in the patient's blood. It must be kept in mind that the peptides and compositions of the present invention may generally be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the minimization of extraneous substances and the relative nontoxic nature of the peptides, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these peptide compositions.

For therapeutic use, administration should begin at the first sign of viral infection or the detection or surgical removal of tumors or shortly after diagnosis in the case of acute infection. This is followed by boosting doses until at least symptoms are substantially abated and for a period thereafter. In chronic infection, loading doses

5 followed by boosting doses may be required.

Treatment of an infected individual with the compositions of the invention may hasten resolution of the infection in acutely infected individuals. For those individuals susceptible (or predisposed) to developing chronic infection the compositions are particularly useful in methods for preventing the evolution from acute to chronic  
10 infection. Where the susceptible individuals are identified prior to or during infection, for instance, as described herein, the composition can be targeted to them, minimizing need for administration to a larger population.

The peptide compositions can also be used for the treatment of chronic infection and to stimulate the immune system to eliminate virus-infected cells in carriers.  
15 It is important to provide an amount of immuno-potentiating peptide in a formulation and mode of administration sufficient to effectively stimulate a cytotoxic T cell response. Thus, for treatment of chronic infection, a representative dose is in the range of about 1.0  $\mu\text{g}$  to about 5000  $\mu\text{g}$ , preferably about 5  $\mu\text{g}$  to 1000  $\mu\text{g}$  for a 70 kg patient per dose. Immunizing doses followed by boosting doses at established intervals, e.g., from one to  
20 four weeks, may be required, possibly for a prolonged period of time to effectively immunize an individual. In the case of chronic infection, administration should continue until at least clinical symptoms or laboratory tests indicate that the viral infection has been eliminated or substantially abated and for a period thereafter.

The pharmaceutical compositions for therapeutic treatment are intended  
25 for parenteral, topical, oral or local administration. Preferably, the pharmaceutical compositions are administered parenterally, e.g., intravenously, subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for parenteral administration which comprise a solution of the immunogenic peptides dissolved or suspended in an acceptable carrier, preferably an aqueous carrier. A variety  
30 of aqueous carriers may be used, e.g., water, buffered water, 0.8% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined

with a sterile solution prior to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.

The concentration of CTL stimulatory peptides of the invention in the pharmaceutical formulations can vary widely, i.e., from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

The peptides of the invention may also be administered via liposomes, which serve to target the peptides to a particular tissue, such as lymphoid tissue, or targeted selectively to infected cells, as well as increase the half-life of the peptide composition. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. In these preparations the peptide to be delivered is incorporated as part of a liposome, alone or in conjunction with a molecule which binds to, e.g., a receptor prevalent among lymphoid cells, such as monoclonal antibodies which bind to the CD45 antigen, or with other therapeutic or immunogenic compositions. Thus, liposomes either filled or decorated with a desired peptide of the invention can be directed to the site of lymphoid cells, where the liposomes then deliver the selected therapeutic/immunogenic peptide compositions. Liposomes for use in the invention are formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size, acid lability and stability of the liposomes in the blood stream. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369, incorporated herein by reference.

For targeting to the immune cells, a ligand to be incorporated into the liposome can include, e.g., antibodies or fragments thereof specific for cell surface determinants of the desired immune system cells. A liposome suspension containing a peptide may be administered intravenously, locally, topically, etc. in a dose which varies

according to, inter alia, the manner of administration, the peptide being delivered, and the stage of the disease being treated.

For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more peptides of the invention, and more preferably at a concentration of 25%-75%.

For aerosol administration, the immunogenic peptides are preferably supplied in finely divided form along with a surfactant and propellant. Typical percentages of peptides are 0.01%-20% by weight, preferably 1%-10%. The surfactant must, of course, be nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1%-20% by weight of the composition, preferably 0.25-5%. The balance of the composition is ordinarily propellant. A carrier can also be included, as desired, as with, e.g., lecithin for intranasal delivery.

In another aspect the present invention is directed to vaccines which contain as an active ingredient an immunogenically effective amount of an immunogenic peptide as described herein. The peptide(s) may be introduced into a host, including humans, linked to its own carrier or as a homopolymer or heteropolymer of active peptide units. Such a polymer has the advantage of increased immunological reaction and, where different peptides are used to make up the polymer, the additional ability to induce antibodies and/or CTLs that react with different antigenic determinants of the virus or tumor cells. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. The vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant. Adjuvants such as incomplete Freund's adjuvant,

aluminum phosphate, aluminum hydroxide, or alum are materials well known in the art. And, as mentioned above, CTL responses can be primed by conjugating peptides of the invention to lipids, such as P<sub>3</sub>CSS. Upon immunization with a peptide composition as described herein, via injection, aerosol, oral, transdermal or other route, the immune  
 5 system of the host responds to the vaccine by producing large amounts of CTLs specific for the desired antigen, and the host becomes at least partially immune to later infection, or resistant to developing chronic infection.

Vaccine compositions containing the peptides of the invention are administered to a patient susceptible to or otherwise at risk of viral infection or cancer to  
 10 elicit an immune response against the antigen and thus enhance the patient's own immune response capabilities. Such an amount is defined to be an "immunogenically effective dose." In this use, the precise amounts again depend on the patient's state of health and weight, the mode of administration, the nature of the formulation, etc., but generally range from about 1.0 µg to about 5000 µg per 70 kilogram patient, more commonly from  
 15 about 10 µg to about 500 µg mg per 70 kg of body weight.

In some instances it may be desirable to combine the peptide vaccines of the invention with vaccines which induce neutralizing antibody responses to the virus of interest, particularly to viral envelope antigens.

For therapeutic or immunization purposes, nucleic acids encoding one or  
 20 more of the peptides of the invention can also be administered to the patient. A number of methods are conveniently used to deliver the nucleic acids to the patient. For instance, the nucleic acid can be delivered directly, as "naked DNA". This approach is described, for instance, in Wolff et. al., *Science* 247:1465-1468 (1990) as well as U.S. Patent Nos. 5,580,859 and 5,589,466. The nucleic acids can also be administered using ballistic  
 25 delivery as described, for instance, in U.S. Patent No. 5,204,253. Particles comprised solely of DNA can be administered. Alternatively, DNA can be adhered to particles, such as gold particles. The nucleic acids can also be delivered complexed to cationic compounds, such as cationic lipids. Lipid-mediated gene delivery methods are described, for instance, in WO 96/18372; WO 93/24640; Mannino and Gould-Fogerite (1988)  
 30 BioTechniques 6(7):682-691; Rose U.S. Pat No. 5,279,833; WO 91/06309; and Felgner et al. (1987) Proc. Natl. Acad. Sci. USA 84: 7413-7414. The peptides of the invention can also be expressed by attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus as a vector to express nucleotide sequences that encode

the peptides of the invention. Upon introduction into an acutely or chronically infected host or into a noninfected host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits a host CTL response. Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S. Patent No.

5 4,722,848, incorporated herein by reference. Another vector is BCG (Bacille Calmette Guerin). BCG vectors are described in Stover et al. (Nature 351:456-460 (1991)) which is incorporated herein by reference. A wide variety of other vectors useful for therapeutic administration or immunization of the peptides of the invention, e.g., Salmonella typhi vectors and the like, will be apparent to those skilled in the art from the description  
10 herein.

A preferred means of administering nucleic acids encoding the peptides of the invention uses minigene constructs encoding multiple epitopes of the invention. To create a DNA sequence encoding the selected CTL epitopes (minigene) for expression in human cells, the amino acid sequences of the epitopes are reverse translated. A human  
15 codon usage table is used to guide the codon choice for each amino acid. These epitope-encoding DNA sequences are directly adjoined, creating a continuous polypeptide sequence. To optimize expression and/or immunogenicity, additional elements can be incorporated into the minigene design. Examples of amino acid sequence that could be reverse translated and included in the minigene sequence include: helper T lymphocyte  
20 epitopes, a leader (signal) sequence, and an endoplasmic reticulum retention signal. In addition, MHC presentation of CTL epitopes may be improved by including synthetic (e.g. poly-alanine) or naturally-occurring flanking sequences adjacent to the CTL epitopes.

The minigene sequence is converted to DNA by assembling  
25 oligonucleotides that encode the plus and minus strands of the minigene. Overlapping oligonucleotides (30-100 bases long) are synthesized, phosphorylated, purified and annealed under appropriate conditions using well known techniques. The ends of the oligonucleotides are joined using T4 DNA ligase. This synthetic minigene, encoding the CTL epitope polypeptide, can then be cloned into a desired expression vector.

30 Standard regulatory sequences well known to those of skill in the art are included in the vector to ensure expression in the target cells. Several vector elements are required: a promoter with a down-stream cloning site for minigene insertion; a polyadenylation signal for efficient transcription termination; an E. coli origin of

replication; and an *E. coli* selectable marker (e.g. ampicillin or kanamycin resistance). Numerous promoters can be used for this purpose, e.g., the human cytomegalovirus (hCMV) promoter. See, U.S. Patent Nos. 5,580,859 and 5,589,466 for other suitable promoter sequences.

5 Additional vector modifications may be desired to optimize minigene expression and immunogenicity. In some cases, introns are required for efficient gene expression, and one or more synthetic or naturally-occurring introns could be incorporated into the transcribed region of the minigene. The inclusion of mRNA stabilization sequences can also be considered for increasing minigene expression. It has recently been proposed that immunostimulatory sequences (ISSs or CpGs) play a role in the immunogenicity of DNA vaccines. These sequences could be included in the vector, outside the minigene coding sequence, if found to enhance immunogenicity.

In some embodiments, a bioisotonic expression vector, to allow production of the minigene-encoded epitopes and a second protein included to enhance or decrease immunogenicity can be used. Examples of proteins or polypeptides that could beneficially enhance the immune response if co-expressed include cytokines (e.g., IL2, IL12, GM-CSF), cytokine-inducing molecules (e.g. LeIF) or costimulatory molecules. Helper (HTL) epitopes could be joined to intracellular targeting signals and expressed separately from the CTL epitopes. This would allow direction of the HTL epitopes to a cell compartment different than the CTL epitopes. If required, this could facilitate more efficient entry of HTL epitopes into the MHC class II pathway, thereby improving CTL induction. In contrast to CTL induction, specifically decreasing the immune response by co-expression of immunosuppressive molecules (e.g. TGF- $\beta$ ) may be beneficial in certain diseases.

25 Once an expression vector is selected, the minigene is cloned into the polylinker region downstream of the promoter. This plasmid is transformed into an appropriate *E. coli* strain, and DNA is prepared using standard techniques. The orientation and DNA sequence of the minigene, as well as all other elements included in the vector, are confirmed using restriction mapping and DNA sequence analysis.

30 Bacterial cells harboring the correct plasmid can be stored as a master cell bank and a working cell bank.

Therapeutic quantities of plasmid DNA are produced by fermentation in *E. coli*, followed by purification. Aliquots from the working cell bank are used to inoculate

fermentation medium (such as Terrific Broth), and grown to saturation in shaker flasks or a bioreactor according to well known techniques. Plasmid DNA can be purified using standard bioseparation technologies such as solid phase anion-exchange resins supplied by Quiagen. If required, supercoiled DNA can be isolated from the open circular and

5 linear forms using gel electrophoresis or other methods.

Purified plasmid DNA can be prepared for injection using a variety of formulations. The simplest of these is reconstitution of lyophilized DNA in sterile phosphate-buffer saline (PBS). A variety of methods have been described, and new techniques may become available. As noted above, nucleic acids are conveniently

10 formulated with cationic lipids. In addition, glycolipids, fusogenic liposomes, peptides and compounds referred to collectively as protective, interactive, non-condensing (PINC) could also be complexed to purified plasmid DNA to influence variables such as stability, intramuscular dispersion, or trafficking to specific organs or cell types.

Target cell sensitization can be used as a functional assay for expression

15 and MHC class I presentation of minigene-encoded CTL epitopes. The plasmid DNA is introduced into a mammalian cell line that is suitable as a target for standard CTL chromium release assays. The transfection method used will be dependent on the final formulation. Electroporation can be used for "naked" DNA, whereas cationic lipids allow direct in vitro transfection. A plasmid expressing green fluorescent protein (GFP) can be

20 co-transfected to allow enrichment of transfected cells using fluorescence activated cell sorting (FACS). These cells are then chromium-51 labeled and used as target cells for epitope-specific CTL lines. Cytolysis, detected by <sup>51</sup>Cr release, indicates production of MHC presentation of minigene-encoded CTL epitopes.

*In vivo* immunogenicity is a second approach for functional testing of

25 minigene DNA formulations. Transgenic mice expressing appropriate human MHC molecules are immunized with the DNA product. The dose and route of administration are formulation dependent (e.g. IM for DNA in PBS, IP for lipid-complexed DNA). Twenty-one days after immunization, splenocytes are harvested and restimulated for 1 week in the presence of peptides encoding each epitope being tested. These effector cells

30 (CTLs) are assayed for cytolysis of peptide-loaded, chromium-51 labeled target cells using standard techniques. Lysis of target cells sensitized by MHC loading of peptides corresponding to minigene-encoded epitopes demonstrates DNA vaccine function for *in vivo* induction of CTLs.

Antigenic peptides may be used to elicit CTL *ex vivo*, as well. The resulting CTL, can be used to treat chronic infections (viral or bacterial) or tumors in patients that do not respond to other conventional forms of therapy, or will not respond to a peptide vaccine approach of therapy. *Ex vivo* CTL responses to a particular pathogen (infectious agent or tumor antigen) are induced by incubating in tissue culture the patient's CTL precursor cells (CTLp) together with a source of antigen-presenting cells (APC) and the appropriate immunogenic peptide. After an appropriate incubation time (typically 1-4 weeks), in which the CTLp are activated and mature and expand into effector CTL, the cells are infused back into the patient, where they will destroy their specific target cell (an infected cell or a tumor cell). In order to optimize the *in vitro* conditions for the generation of specific cytotoxic T cells, the culture of stimulator cells is maintained in an appropriate serum-free medium.

Prior to incubation of the stimulator cells with the cells to be activated, e.g., precursor CD8+ cells, an amount of antigenic peptide is added to the stimulator cell culture, of sufficient quantity to become loaded onto the human Class I molecules to be expressed on the surface of the stimulator cells. In the present invention, a sufficient amount of peptide is an amount that will allow about 200, and preferably 200 or more, human Class I MHC molecules loaded with peptide to be expressed on the surface of each stimulator cell. Preferably, the stimulator cells are incubated with >20µg/ml peptide.

Resting or precursor CD8+ cells are then incubated in culture with the appropriate stimulator cells for a time period sufficient to activate the CD8+ cells. Preferably, the CD8+ cells are activated in an antigen-specific manner. The ratio of resting or precursor CD8+ (effector) cells to stimulator cells may vary from individual to individual and may further depend upon variables such as the amenability of an individual's lymphocytes to culturing conditions and the nature and severity of the disease condition or other condition for which the within-described treatment modality is used. Preferably, however, the lymphocyte:stimulator cell ratio is in the range of about 30:1 to 300:1. The effector/stimulator culture may be maintained for as long a time as is necessary to stimulate a therapeutically useable or effective number of CD8+ cells.

The induction of CTL *in vitro* requires the specific recognition of peptides that are bound to allele specific MHC class I molecules on APC. The number of specific MHC/peptide complexes per APC is crucial for the stimulation of CTL, particularly in primary immune responses. While small amounts of peptide/MHC complexes per cell

are sufficient to render a cell susceptible to lysis by CTL, or to stimulate a secondary CTL response, the successful activation of a CTL precursor (pCTL) during primary response requires a significantly higher number of MHC/peptide complexes. Peptide loading of empty major histocompatibility complex molecules on cells allows the induction of primary cytotoxic T lymphocyte responses. Peptide loading of empty major histocompatibility complex molecules on cells enables the induction of primary cytotoxic T lymphocyte responses.

Since mutant cell lines do not exist for every human MHC allele, it is advantageous to use a technique to remove endogenous MHC-associated peptides from the surface of APC, followed by loading the resulting empty MHC molecules with the immunogenic peptides of interest. The use of non-transformed (non-tumorigenic), non-infected cells, and preferably, autologous cells of patients as APC is desirable for the design of CTL induction protocols directed towards development of *ex vivo* CTL therapies. This application discloses methods for stripping the endogenous MHC-associated peptides from the surface of APC followed by the loading of desired peptides.

A stable MHC class I molecule is a trimeric complex formed of the following elements: 1) a peptide usually of 8 - 10 residues, 2) a transmembrane heavy polymorphic protein chain which bears the peptide-binding site in its  $\alpha 1$  and  $\alpha 2$  domains, and 3) a non-covalently associated non-polymorphic light chain,  $\beta_2$  microglobulin. Removing the bound peptides and/or dissociating the  $\beta_2$  microglobulin from the complex renders the MHC class I molecules nonfunctional and unstable, resulting in rapid degradation. All MHC class I molecules isolated from PBMCs have endogenous peptides bound to them. Therefore, the first step is to remove all endogenous peptides bound to MHC class I molecules on the APC without causing their degradation before exogenous peptides can be added to them.

Two possible ways to free up MHC class I molecules of bound peptides include lowering the culture temperature from 37°C to 26°C overnight to destabilize  $\beta_2$  microglobulin and stripping the endogenous peptides from the cell using a mild acid treatment. The methods release previously bound peptides into the extracellular environment allowing new exogenous peptides to bind to the empty class I molecules. The cold-temperature incubation method enables exogenous peptides to bind efficiently to the MHC complex, but requires an overnight incubation at 26°C which may slow the cell's metabolic rate. It is also likely that cells not actively synthesizing MHC molecules

(e.g., resting PBMC) would not produce high amounts of empty surface MHC molecules by the cold temperature procedure.

Harsh acid stripping involves extraction of the peptides with trifluoroacetic acid, pH 2, or acid denaturation of the immunoaffinity purified class I-peptide complexes.

5 These methods are not feasible for CTL induction, since it is important to remove the endogenous peptides while preserving APC viability and an optimal metabolic state which is critical for antigen presentation. Mild acid solutions of pH 3 such as glycine or citrate-phosphate buffers have been used to identify endogenous peptides and to identify tumor associated T cell epitopes. The treatment is especially effective, in that only the  
10 MHC class I molecules are destabilized (and associated peptides released), while other surface antigens remain intact, including MHC class II molecules. Most importantly, treatment of cells with the mild acid solutions do not affect the cell's viability or metabolic state. The mild acid treatment is rapid since the stripping of the endogenous peptides occurs in two minutes at 4°C and the APC is ready to perform its function after  
15 the appropriate peptides are loaded. The technique is utilized herein to make peptide-specific APCs for the generation of primary antigen-specific CTL. The resulting APC are efficient in inducing peptide-specific CD8+ CTL.

Activated CD8+ cells may be effectively separated from the stimulator cells using one of a variety of known methods. For example, monoclonal antibodies  
20 specific for the stimulator cells, for the peptides loaded onto the stimulator cells, or for the CD8+ cells (or a segment thereof) may be utilized to bind their appropriate complementary ligand. Antibody-tagged molecules may then be extracted from the stimulator-effector cell admixture via appropriate means, e.g., via well-known immunoprecipitation or immunoassay methods.

25 Effective, cytotoxic amounts of the activated CD8+ cells can vary between *in vitro* and *in vivo* uses, as well as with the amount and type of cells that are the ultimate target of these killer cells. The amount will also vary depending on the condition of the patient and should be determined via consideration of all appropriate factors by the practitioner. Preferably, however, about  $1 \times 10^6$  to about  $1 \times 10^{12}$ , more preferably about  
30  $1 \times 10^8$  to about  $1 \times 10^{11}$ , and even more preferably, about  $1 \times 10^9$  to about  $1 \times 10^{10}$  activated CD8+ cells are utilized for adult humans, compared to about  $5 \times 10^6$  -  $5 \times 10^7$  cells used in mice.

Preferably, as discussed above, the activated CD8+ cells are harvested from the cell culture prior to administration of the CD8+ cells to the individual being treated. It is important to note, however, that unlike other present and proposed treatment modalities, the present method uses a cell culture system that is not tumorigenic.

- 5 Therefore, if complete separation of stimulator cells and activated CD8+ cells is not achieved, there is no inherent danger known to be associated with the administration of a small number of stimulator cells, whereas administration of mammalian tumor-promoting cells may be extremely hazardous.

10 Methods of re-introducing cellular components are known in the art and include procedures such as those exemplified in U.S. Patent No. 4,844,893 to Honsik, et al. and U.S. Patent No. 4,690,915 to Rosenberg. For example, administration of activated CD8+ cells via intravenous infusion is appropriate.

The immunogenic peptides of this invention may also be used to make monoclonal antibodies. Such antibodies may be useful as potential diagnostic or  
15 therapeutic agents.

The peptides may also find use as diagnostic reagents. For example, a peptide of the invention may be used to determine the susceptibility of a particular individual to a treatment regimen which employs the peptide or related peptides, and thus may be helpful in modifying an existing treatment protocol or in determining a prognosis  
20 for an affected individual. In addition, the peptides may also be used to predict which individuals will be at substantial risk for developing chronic infection.

To identify peptides of the invention, class I antigen isolation, and isolation and sequencing of naturally processed peptides was carried out as described in the related applications. These peptides were then used to define specific binding motifs  
25 for each of the following alleles A3.2, A1, A11, and A24.1. These motifs are described on page 3, above. The motifs described in Tables 8-11, below, are defined from pool sequencing data of naturally processed peptides as described in the related applications.

TABLE 8

## Summary

HLA-A3.2 Allele-Specific Motif

Position	Conserved Residues
1	-

2	V,L,M
3	Y,D
4	-
5	-
6	-
7	I
8	Q,N
9	K
10	K

TABLE 9

## Summary

HLA-A1 Allele-Specific Motif

Position	Conserved Residues
1	-
2	S,T
3	D,E
4	P
5	-
6	-
7	L
8	-
9	Y
10	K

TABLE 10

## Summary

HLA-A11 Allele-Specific Motif

Position	Conserved Residues
1	-
2	T,V

3	M,F
4	-
5	-
6	-
7	-
8	Q
9	K
10	K

TABLE 11

## Summary

HLA-A24.1 Allele-Specific Motif

Position	Conserved Residues
1	-
2	Y
3	I,M
4	D,E,G,K,P
5	L,M,N
6	V
7	N,V
8	A,E,K,Q,S
9	F,L
10	F,A

Example 2

5

Identification of immunogenic peptides

Using the motifs identified above for various MHC class I allele amino acid sequences from various pathogens and tumor-related proteins were analyzed for the presence of these motifs. Screening was carried out described in the related applications. Table 12 provides the results of searches of the antigens.

10

Table 12

Peptide	AA	Sequence	Source	A*0301	A*1101
28.0719	10	ILEQWVAGRK	HDV.nuc.16	0.0170	0.0012
28.0727	10	LSAGGKNLSK	HDV.nuc.115	0.0097	0.0150
1259.02	11	STDTVDTVLEK	Flu.HA.29	0.0001	0.0670
1259.04	9	GIAPLQLGK	Flu.HA.63	0.6100	0.2000
1259.06	10	VTAACSHAGK	Flu.HA.149	0.0380	0.0490
1259.08	9	GIHHPNSK	Flu.HA.195	0.1300	0.0140
1259.10	10	RMNYYWTLLK	Flu.HA.243	2.5000	2.3000
1259.12	11	ITNKVNSVIEK	Flu.HA.392	0.0200	0.0670
1259.13	11	KMNIQFTAVGK	Flu.HA.402	0.0280	0.0092
1259.14	9	NIQFTAVGK	Flu.HA.404	0.0017	0.0330
1259.16	11	AVGKEFNKLEK	Flu.HA.409	0.0210	0.0460
1259.19	11	KVKSQLKNNAK	Flu.HA.465	0.0470	0.0031
1259.20	11	SVRNGTYDYPK	Flu.HA.495	0.0410	0.1400
1259.21	9	SIIPSGPLK	Flu.VMT1.13	0.7800	8.8000
1259.25	10	RMVLASTTAK	Flu.VMT1.178	0.5500	0.0350
1259.26	9	MVLASTTAK	Flu.VMT1.179	1.7000	1.4000
1259.28	10	RMGVQMQRFK	Flu.VMT1.243	0.1000	0.0059
1259.33	10	ATEIRASVGK	Flu.VNUC.22	0.1400	0.3000
1259.37	11	TMVMELVRMIK	Flu.VNUC.188	0.0890	0.0310
1259.43	10	RVLSFIKGTK	Flu.VNUC.342	0.8000	0.0830
F119.01	9	MSLQRQFLR	ORF3P	0.2000	0.7200
F119.02	9	LLGPGRPYR	TRP.197	0.0190	0.0091
F119.03	9	LLGPGRPYK	TRP.197K9	2.2000	0.6800
34.0019	8	RVYPELPK	CEA.139	0.0130	0.0440
34.0020	8	TVSAELPK	CEA.495	0.0037	0.0320
34.0021	8	TVYAEPPK	CEA.317	0.0160	0.0220
34.0029	8	TINYTLWR	MAGE2.74	0.0140	0.0550
34.0030	8	LVHFLLLK	MAGE2.116	0.0290	0.1500
34.0031	8	SVFAHPRK	MAGE2.237	0.1410	0.0810
34.0043	8	KVLHHMVK	MAGE3.285	0.0580	0.0190
34.0050	8	RVCACPGR	p53.273	0.3500	0.0490

34.0051	8	KMFCQLAK	p53.132	0.3800	0.3600
34.0062	8	RAHSSHLK	p53.363	0.5500	0.0071
34.0148	9	FVSNLATGR	CEA.656	0.0019	0.0490
34.0152	9	RLQLSNGNK	CEA.546	0.0250	0.0110
34.0153	9	RINGIPQQK	CEA.628	0.0400	0.0780
34.0154	9	KIRKYTMRK	HER2/neu.681	0.0620	0.0055
34.0155	9	LVHFLLLKK	MAGE2.116	0.5220	1.4000
34.0156	9	SMLEVFEGK	MAGE2.226	0.0950	1.6000
34.0157	9	SSFSTTINK	MAGE2.69	0.1600	2.0000
34.0158	9	TSYVKVLHK	MAGE2.281	0.5300	0.1500
34.0159	9	VIFSKASEK	MAGE2.149	0.4900	0.0530
34.0160	9	GSVVGNWQK	MAGE3.130	0.0040	0.2060
34.0161	9	SSLPTTMNK	MAGE3.69	0.6180	0.7100
34.0162	9	SVLEVFEGK	MAGE3.226	0.1330	0.9000
34.0171	9	SSBMGGMNK	p53.240	0.5440	1.1000
34.0172	9	SSCMGGMNK	p53.240	0.0090	0.0490
34.0211	10	RTLTLFNVTK	CEA.554	0.2200	1.3000
34.0212	10	TISPLNTSYK	CEA.241	0.1800	0.0330
34.0214	10	STTINYTLWK	MAGE2.72	0.0870	0.6500
34.0215	10	ASSLPTTMNK	MAGE3.68	0.0420	0.0270
34.0225	10	KTYQGSYGFK	p53.101	0.4900	0.4200
34.0226	10	VVRRBPHHEK	p53.172	0.1800	0.2100
34.0228	10	GLAPPQHLIK	p53.187	0.0570	0.0160
34.0229	10	NSSCMGGMNK	p53.239	0.0071	0.0290
34.0230	10	SSBMGGMNRK	p53.240	0.0420	0.1600
34.0232	10	RVCACPGRDK	p53.273	0.0190	0.0250
34.0295	11	KTITVSAELPK	CEA.492	0.3600	0.1600
34.0296	11	TTITVYAEPPK	CEA.314	0.0200	0.0280
34.0298	11	PTISPSYTYR	CEA.418	(0.0002)	0.1300
34.0301	11	GLLGDNQVMPK	MAGE2.188	0.0780	0.0047
34.0306	11	MVELVHFLLLK	MAGE2.113	0.0200	0.0120
34.0308	11	FSTTINYTLWR	MAGE2.71	0.0110	0.0170

34.0311	11	GLLGDNQIMPK	MAGE3.188	0.1300	0.0570
34.0317	11	RLGFLHSGTAK	p53.110	0.0430	0.0001
34.0318	11	ALNKMFCQLAK	p53.129	0.4400	0.0420
34.0323	11	RVCACPGRR	p53.273	0.0290	0.0290
34.0324	11	LSQETFSDLWK	p53.14	(0.0009)	0.0470
34.0328	11	RAHSSHLKSKK	p53.363	0.0270	0.0038
34.0329	11	VTCTYSPALNK	p53.122	0.0700	0.1200
34.0330	11	GTRVRAMAIYK	p53.154	1.1000	0.3300
34.0332	11	STSRHKKLMFK	p53.376	0.3100	0.1300
40.0107	9	LAARNVLVK	Her2/neu.846	0.0580	0.0285
40.0109	9	MALESILRR	Her2/neu.889	0.0034	0.0237
40.0145	10	ISWLGLRSLR	Her2/neu.450	0.0410	0.0027
40.0147	10	GSGAFGTVYK	Her2/neu.727	0.0660	0.1300
40.0153	10	ASPLDSTFYR	Her2/neu.997	0.0003	0.0670

### Example 3

#### Identification of immunogenic peptides

5 Using the B7-like supermotifs identified in the related applications described above, sequences from various pathogens and tumor-related proteins were analyzed for the presence of these motifs. Screening was carried out described in the related applications. Table 13 provides the results of searches of the antigens.

10 Table 13

Peptide	Sequence	Source
40.0013	SPGLSAGI	CEA.680I8
15 40.0022	KPYDGIPA	Her2/neu.921
40.0023	KPYDGIPI	Her2/neu.921I8
40.0050	APRMPEAA	p53.63
40.0051	APRMPEAI	p53.63I8
40.0055	APAAPTPI	p53.76I8

	40.0057	APTPAAPI	p53.79I8
	40.0059	TPAAPAPI	p53.81I8
	40.0061	APAPAPSI	p53.84I8
	40.0062	SPALNKMF	p53.127
5	40.0063	SPALNKMI	p53.127I8
	40.0117	SPSAPPRI	CEA.3I9
	40.0119	PPHRWCIPI	CEA.7I9
	40.0120	GPAYSGREI	CEA.92
	40.0156	MPNQAQMRILI	Her2/neu.706I10
10	40.0157	MPYGCLLDHVI	Her2/neu.801I10
	40.0161	APPHRWCIPIW	CEA.6
	40.0162	APPHRWCIPI	CEA.6I10
	40.0163	IPWQRLLTA	CEA.13
	40.0164	IPWQRLLTI	CEA.13I10
15	40.0166	LPQHILFGYSI	CEA.58I10
	40.0201	RPRFRELVSEF	Her2/neu.966
	40.0202	RPRFRELVSEI	Her2/neu.966I11
	40.0205	PPSPREGPLPA	Her2/neu.1149
	40.0206	PPSPREGPLPI	Her2/neu.1149I11
20	40.0207	GPLPAARPAGA	Her2/neu.1155
	40.0208	GPLPAARPAGI	Her2/neu.1155I11
	40.0231	APAPAAPTPAA	p53.74
	40.0232	APAPAAPTPAI	p53.74I11
	40.0233	APAAPTPAAPA	p53.76
25	40.0234	APAAPTPAAPI	p53.76I11
	45.0003	IPWQRLLI	CEA.13.I8
	45.0004	LPQHILFGI	CEA.58.I8
	45.0007	RPGVNLSI	CEA.428.I8
	45.0010	IPQQHTQI	CEA.632.I8
30	45.0011	TPNNNGTI	CEA.646.I8
	45.0016	CPLHNQEI	Her2/neu.315.I8
	45.0017	KPCARVCI	Her2/neu.336.I8
	45.0019	WPDSLPI	Her2/neu.415.I8

	45.0023	SPYVSRLI	Her2/neu.779.I8
	45.0024	VPIKWMAI	Her2/neu.884.I8
	45.0026	RPRFRELI	Her2/neu.966.I8
	45.0028	APGAGGMI	Her2/neu.1036.I8
5	45.0031	SPGKNGVI	Her2/neu.1174.I8
	45.0037	SPQGASSI	MAGE3.64.I8
	45.0038	YPLWSQSI	MAGE3.77.I8
	45.0044	SPLPSQAI	p53.33.I8
	45.0046	MPEAAPPI	p53.66.I8
10	45.0047	APAPSWPI	p53.86.I8
	45.0051	KPVEDKDAI	CEA.155.I9
	45.0054	IPQQHTQVI	CEA.632.I9
	45.0060	APPVAPAPI	p53.70.I9
	45.0062	APAAPTPAI	p53.76.I9
15	45.0064	PPGTRVRAI	p53.152.I9
	45.0065	APPQHLIRI	p53.189.I9
	45.0071	IPQQHTQVLI	CEA.632.I10
	45.0072	SPGLSAGATI	CEA.680.I10
	45.0073	SPMCKGSRCI	Her2/neu.196.I10
20	45.0074	MPNPEGRTYI	Her2/neu.282.I10
	45.0076	CPLHNQEVTI	Her2/neu.315.I10
	45.0079	KPDLSYMPII	Her2/neu.605.I10
	45.0080	TPSGAMPNQI	Her2/neu.701.I10
	45.0084	GPASPLDSTI	Her2/neu.995.I10
25	45.0091	APPVAPAPAI	p53.70.I10
	45.0092	APAPAAPTPI	p53.74.I10
	45.0093	APTPAAPAPI	p53.79.I10
	45.0094	APSWPLSSSI	p53.88.I10
	45.0103	APTISPLNTSI	CEA.239.I11
30	45.0108	SPSYTTYRPGI	CEA.421.I11
	45.0117	CPSGVKPDLSI	Her2/neu.600.I11
	45.0118	SPLTSIISAVI	Her2/neu.649.I11
	45.0119	IPDGENVKIPI	Her2/neu.740.I11

	45.0124	SPLDSTFYRSI	Her2/neu.998.I11
	45.0128	LPAARPAGATI	Her2/neu.1157.I11
	45.0134	HPRKLLMQDLI	MAGE2.241.I11
	45.0135	GPRALIETSYI	MAGE2.274.I11
5	45.0139	GPRALVETSYI	MAGE3.274.I11
	45.0140	APRMPEAAPPI	p53.63.I11
	45.0141	VPSQKTYQGS I	p53.97.I11
	1145.10	FPHCLAFAY	HBV POL 541 analog
	1145.09	FPVCLAFSY	HBV POL 541 analog
10	26.0570	YPALMPLYACI	HBV.pol.645

The above description is provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

WHAT IS CLAIMED IS:

1                   1.       A composition comprising an immunogenic peptide having an  
2 HLA-A2.1 binding motif, which immunogenic peptide is selected from a group  
3 consisting of:

4                   AILTFGSFV,  
5                   HLRDFALAV,  
6                   ALLGSIALL,  
7                   ALLATILAA,  
8                   LLATILAAV,  
9                   RLFADLAA,  
10                  YLSKCTLAV,  
11                  LVYHIYSKI,  
12                  SMYLCILSA,  
13                  YLCILSALV,  
14                  VMFSYLQSL,  
15                  RLHVVAYSA,  
16                  GLQTLGAFV,  
17                  FVEEQMTWA,  
18                  QMTWAQTVV,  
19                  IILDTAIFV,  
20                  AIFVCNAFV,  
21                  AMGNRLVEA,  
22                  RLVEACNLL  
23                  TLSIVTFSL,  
24                  KLSVLLLEV,  
25                  LLEVNRSV,  
26                  FVSSPTLPV,  
27                  AMLVLLAEI,  
28                  QMARLAWEA,  
29                  VLAIEGIFMA,  
30                  YLYHPLLSPV,  
31                  SLFEAMLANV,

32 STTGINQLGL,  
33 LAILTFGSFV,  
34 ALLGSIALLA,  
35 ALLATILAAV,  
36 LLATILAAVA,  
37 RLFADELAAL,  
38 YLSKCTLAVL,  
39 LLVYHIYSKI,  
40 SMYLCILSAL,  
41 HLHRQMLSFV,  
42 LLCGKTGAFL,  
43 ETLIVTFSL,  
44 VMCTYSPPL,  
45 KLFCQLAKT,  
46 ATPPAGSRV,  
47 FLQSGTAKSV,  
48 CMDRGLTVFV,  
49 VLLNWWRWRL,  
50 GVFTGLTHI,  
51 QMWKCLIRL,  
52 IMTCMSADL,  
53 ALAAYCLST,  
54 VLSGKPAII,  
55 FISGIQYLA,  
56 YIMTCMSADL,  
57 AIASLMAFTA,  
58 GLAGAAIGSV,  
59 MIGVLVGV,  
60 VLPLAYISL,  
61 SLGCIFFPL,  
62 PLAYISLFL,  
63 LMLFYQVWA,  
64 NISIYNYFV,

65 NISVYNYFV,  
66 FVWTHYYSV,  
67 FLTWHRYHL,  
68 LTWHRYHLL,  
69 MLQEPSFSL,  
70 SLPYWNFAT,  
71 RLPEPQDVA,  
72 VTQCLEVRV,  
73 LLHTFTDAV,  
74 NMVPFWPPV,  
75 AVVGALLLV,  
76 AVVAALLLV,  
77 LLVAAIFGV,  
78 SMDEANQPL,  
79 VLPLAYISV,  
80 SLGCIFFPV,  
81 PLAYISLFV,  
82 LLLFQQARV,  
83 LMLFYQVWV,  
84 LLPSSGPGV,  
85 NLSIYNYFV,  
86 NLSVYNYFV,  
87 FLWTHYYSV,  
88 SLKKTFLGV,  
89 FLTWHRYHV,  
90 MLQEPSFSV,  
91 SLPYWNFAV,  
92 ALGKNVCDV,  
93 SLLISPNSV,  
94 SLFSQWRVV,  
95 TLGTLCNSV,  
96 RLPEPQDVV,  
97 VLQCLEVRV,

98 SLNSFRNTV,  
99 SLDSFRNTV  
100 FLNGTGGQV  
101 VLLHTFTDV  
102 ALVGALLV  
103 ALVAALLV,  
104 LLVALIFGV,  
105 YLIRARRSV,  
106 SMDEANQPV,  
107 SLGCIFFPLL,  
108 GMCCPDLSPV,  
109 AACNQKILTV  
110 FLTWHRYHLL,  
111 SLHNLAHLFL  
112 LLLVAAIFGV  
113 LLVAAIFGVA,  
114 ALIFGTASYL,  
115 SMDEANQPLL,  
116 LLTDQYQCYA,  
117 SLGCIFFPLV,  
118 FLMLFYQVWV,  
119 ALCDQRVLIV,  
120 ALCNQKILTV,  
121 FLTWHRYHLV,  
122 SLHNLAHLFV,  
123 NLAHLFLNGV,  
124 NMVPFWPPVV,  
125 ILVVAALLV,  
126 LLVALIFGTV,  
127 ALIFGTASYV,  
128 SMDEANQPLV,  
129 LLTDQYQCYV,  
130 LLIQNIIQNDT,

131 IIQNDTGFYTL,  
132 TLFNVTRNDTA  
133 LTLLSVTRNDV  
134 GLYTCQANNSA,  
135 ATVGIMIGVLV,  
136 GLVPPQHLIRV,  
137 GLAPPVHLIRV,  
138 GLAPPEHLIRV,  
139 ILIGVLVGV,  
140 YLIMVKCWMV,  
141 LLGRDSFEV,  
142 FMYSDFHFI,  
143 NMLSTVLGV  
144 SLENFRAYV,  
145 KMAELVHFV,  
146 KLAELVHFV  
147 VLIQRNPQV,  
148 VLLGVVFGV,  
149 SLISAVVGV,  
150 YMIMVKBWMI,  
151 YLIMVKBWMV,  
152 KLWEELSVV,  
153 AMBRWGLLV,  
154 IJIGVLVGV,  
155 ATVGIIJGV,  
156 SJPPPGTRV,  
157 LVFGIELJEV,  
158 ILGFVFTL,  
159 KIFGSLAFL,  
160 YLQLVFGIEV,  
161 MMNDQLMFL,  
162 ALVLAGGFFL,  
163 WLCAGALVL,

164 MVFELANSI,  
 165 RMMNDQLMFL,  
 166 LVLAGGFFL,  
 167 VLAGGFFLL,  
 168 LLHETDSAV,  
 169 LMYSLVHNL,  
 170 QLMFLERAFL,  
 171 LMFLERAFL,  
 172 KLGSGNDFEV,  
 173 LLQERGVAYI,  
 174 GMPEGDLVYV,  
 175 FLDELKAENI,  
 176 ALFDIESKV,  
 177 and GLPSIPVHPI.  
 178  
 179

1 2. A method of inducing a cytotoxic T cell response against a  
 2 preselected antigen in a patient expressing an HLA-A2.1 MHC product, the method  
 3 comprising contacting cytotoxic T cells from the patient with a composition comprising  
 4 an immunogenic peptide selected from the group consisting of:

5 AILTFGSFV,  
 6 HLRDFALAV,  
 7 ALLGSIALL,  
 8 ALLATILAA,  
 9 LLATILAAV,  
 10 RLFADELAA,  
 11 YLSKCTLAV,  
 12 LVYHIYSKI,  
 13 SMYLCILSA,  
 14 YLCILSALV,  
 15 VMFSYLQSL,  
 16 RLHVYAYSA,

17 GLQTLGAFV,  
18 FVEEQMTWA,  
19 QMTWAQTVV,  
20 IILDTAIFV,  
21 AIFVCNAFV,  
22 AMGNRLVEA,  
23 RLVEACNLL  
24 TLSIVTFSL,  
25 KLSVLLLEV,  
26 LLEVNRSV,  
27 FVSSPTLPV,  
28 AMLVLLAEI,  
29 QMARLAWEA,  
30 VLAIEGIFMA,  
31 YLYHPLLSPI,  
32 SLFEAMLANV,  
33 STTGINQLGL,  
34 LAILTFGSFV,  
35 ALLGSIALLA,  
36 ALLATILAAV,  
37 LLATILAAVA,  
38 RLFADELAAL,  
39 YLSKCTLAVL,  
40 LLVYHIYSKI,  
41 SMYLCILSAL,  
42 HLHRQMLSFV,  
43 LLCGKTGAFL,  
44 ETLSIVTFSL,  
45 VMCTYSPPL,  
46 KLFCQLAKT,  
47 ATPPAGSRV,  
48 FLQSGTAKSV,  
49 CMDRGLTVFV,

50 VLLNWWRWRL,  
51 GVFTGLTHI,  
52 QMWKCLIRL,  
53 IMTCMSADL,  
54 ALAAYCLST,  
55 VLSGKPAII,  
56 FISGIQYLA,  
57 YIMTCMSADL,  
58 AIASLMAFTA,  
59 GLAGAAIGSV,  
60 MIGVLVGV,  
61 VLPLAYISL,  
62 SLGCIFFPL,  
63 PLAYISLFL,  
64 LMLFYQVWA,  
65 NISIYNYFV,  
66 NISVYNYFV,  
67 FVWTHYYSV,  
68 FLTWHRYHL,  
69 LTWHRYHLL,  
70 MLQEPSFSL,  
71 SLPYWNFAT,  
72 RLPEPQDVA,  
73 VTQCLEVRV,  
74 LLHTFTDAV,  
75 NMVPFWPPV,  
76 AVVGALLLV,  
77 AVVAALLLV,  
78 LLVAAIFGV,  
79 SMDEANQPL,  
80 VLPLAYISV,  
81 SLGCIFFPV,  
82 PLAYISLFV,

83 LLLFQQARV,  
84 LMLFYQVWV,  
85 LLPSSGPGV,  
86 NLSIYNYFV,  
87 NLSVYNYFV,  
88 FLWTHYYSV,  
89 SLKKTFLGV,  
90 FLTWHRYHV,  
91 MLQEPSFSV,  
92 SLPYWNFAV,  
93 ALGKNVCDV,  
94 SLLISPNSV,  
95 SLFSQWRVV,  
96 TLGTLCNSV,  
97 RLPEPQDVV,  
98 VLQCLEVRV,  
99 SLNSFRNTV,  
100 SLDSFRNTV  
101 FLNGTGGQV  
102 VLLHTFTDV  
103 ALVGALLLV  
104 ALVAALLLV,  
105 LLVALIFGV,  
106 YLIRARRSV,  
107 SMDEANQPV,  
108 SLGCIFFPLL,  
109 GMCCPDLSPV,  
110 AACNQKILTV  
111 FLTWHRYHLL,  
112 SLHNLAHLFL  
113 LLLVAAIFGV  
114 LLVAAIFGVA,  
115 ALIFGTASYL,

116 SMDEANQPLL,  
117 LLTDQYQCYA,  
118 SLGCIFFPLV,  
119 FLMLFYQVWV,  
120 ALCDQRVLIV,  
121 ALCNQKILTV,  
122 FLTWHRYHLV,  
123 SLHNLAHLFV,  
124 NLAHLFLNGV,  
125 NMVPPFWPPVV,  
126 ILVVAALLLV,  
127 LLVALIFGTV,  
128 ALIFGTASYV,  
129 SMDEANQPLV,  
130 LLTDQYQCYV,  
131 LLIQNIIQNDT,  
132 IIQNDTGFYTL,  
133 TLFNVTRNDTA  
134 LTLLSVTRNDV  
135 GLYTCQANNSA,  
136 ATVGIMIGVLV,  
137 GLVPPQHLIRV,  
138 GLAPPVHLIRV,  
139 GLAPPEHLIRV,  
140 ILIGVLVGV,  
141 YLIMVKCWMV,  
142 LLGRDSFEV,  
143 FMYSDFHFI,  
144 NMLSTVLGV  
145 SLENFRAYV,  
146 KMAELVHFV,  
147 KLAELVHFV  
148 VLIQRNPQV,

149 VLLGVVFGV,  
 150 SLISAVVGV,  
 151 YMIMVKBWMI,  
 152 YLIMVKBWMV,  
 153 KLWEELSVV,  
 154 AMBRWGLLV,  
 155 IJIGVLVGV,  
 156 ATVGIIJGV,  
 157 SJPPPGTRV,  
 158 LVFGIELJEV,  
 159 ILGFVFTL,  
 160 KIFGSLAFL,  
 161 YLQLVFGIEV,  
 162 MMNDQLMFL,  
 163 ALVLAGGFFL,  
 164 WLCAGALVL,  
 165 MVFELANSI,  
 166 RMMNDQLMFL,  
 167 LVLAGGFFL,  
 168 VLAGGFFLL,  
 169 LLHETDSAV,  
 170 LMYSLVHNL,  
 171 QLMFLERAFL,  
 172 LMFLERAFL,  
 173 KLGSGNDFEV,  
 174 LLQERGVAYI,  
 175 GMPEGDLVYV,  
 176 FLDELKAENI,  
 177 ALFDIESKV,  
 178 and GLPSIPVHPI.  
 179

1                   3.     A composition comprising an immunogenic peptide selected from  
2     a group consisting of:

3                   RVYPELPK,

4                   TVSAELPK,

5                   TVYAEPPK,

6                   TINYTLWR,

7                   LVHFLLLK,

8                   SVFAHPRK,

9                   KVLHHMVK,

10                  RVCACPGR,

11                  KMFCQLAK,

12                  RAHSSHLK,

13                  FVSNLATGR,

14                  RLQLSNGNK,

15                  RINGIPQQK,

16                  KIRKYTMRK,

17                  LVHFLLLKK,

18                  SMLEVFEGK,

19                  SSFSTTINK,

20                  TSYVKVLHK,

21                  VIFSKASEK,

22	GSVVG NWQK,
23	SSLPT TMNK,
24	SVLEVFEGK,
25	SSBMGG MNK,
26	SSCMGG MNK,
27	RTLTLFNVTK,
28	TISPLNTSYK,
29	STTINYTLWK,
30	ASSLPT TMNK,
31	KTYQGSYGFK,
32	VVRRBPHHEK,
33	GLAPPQH LIK,
34	NSSCMGG MNK,
35	SSBMGG MNRK,
36	RVCACPGRDK,
37	KTITVSAELPK,
38	TTITVYAEPPK,
39	PTISPSYTYR,
40	GLLGDNQVMPK,
41	MVELVHFLLK,
42	FSTTINYTLWR,

43 GLLGDNQIMPK,  
 44 RLGFLHSGTAK,  
 45 ALNKMFCQLAK,  
 46 RVCACPGRDRR,  
 47 LSQETFSDLWK,  
 48 RAHSSHLKSKK,  
 49 VTCTYSPALNK,  
 50 GTRVRAMAIYK,  
 51 STSRHKKLMFK,  
 52 LAARNVLVK,  
 53 MALESILRR,  
 54 ISWLGLRSLR,  
 55 GSGAFGTVYK,  
 56 and ASPLDSTFYR.

1           4.     A method of inducing a cytotoxic T cell response against a  
 2 preselected antigen in a patient, the method comprising contacting cytotoxic T cells from  
 3 the patient with a composition comprising an immunogenic peptide selected from the  
 4 group consisting of:

5           RVYPELPK,  
 6           TVSAELPK,  
 7           TVYAEPPK,  
 8           TINYTLWR,

9	LVHFLLLK,
10	SVFAHPRK,
11	KVLHHMVK,
12	RVCACPGR,
13	KMFCQLAK,
14	RAHSSHLK,
15	FVSNLATGR,
16	RLQLSNGNK,
17	RINGIPQQK,
18	KIRKYTMRK,
19	LVHFLLLKK,
20	SMLEVFEGK,
21	SSFSTTINK,
22	TSYVKVLHK,
23	VIFSKASEK,
24	GSVVGNWQK,
25	SSLPTTMNK,
26	SVLEVFEGK,
27	SSBMGGMNK,
28	SSCMGGMNK,
29	RTLTLFNVTK,

30 TISPLNTSYK,  
31 STTINYTLWK,  
32 ASSLPTTMNK,  
33 KTYQGSYGFK,  
34 VVRRBPHHEK,  
35 GLAPPQHLIK,  
36 NSSCMGGMNK,  
37 SSBMGGMNRK,  
38 RVCACPGRDK,  
39 KTITVSAELPK,  
40 TTITVYAEPPK,  
41 PTISPSYTYR,  
42 GLLGDNQVMPK,  
43 MVELVHFLLLK,  
44 FSTTINYTLWR,  
45 GLLGDNQIMPK,  
46 RLGFLHSGTAK,  
47 ALNKMFCQLAK,  
48 RVCACPGRDRR,  
49 LSQETFSDLWK,  
50 RAHSSHLKSKK,

51 VTCTYSPALNK,  
52 GTRVRAMAIYK,  
53 STSRHKKLMFK,  
54 LAARNVLVK,  
55 MALESILRR,  
56 ISWLGLRSLR,  
57 GSGAFGTVYK,  
58 and ASPLDSTFYR.

1 5. A composition comprising an immunogenic peptide selected from  
2 a group consisting of the peptides listed in Table 13.

1 6. A method of inducing a cytotoxic T cell response against a  
2 preselected antigen in a patient, the method comprising contacting cytotoxic T cells from  
3 the patient with a composition comprising an immunogenic peptide selected from the  
4 group consisting of the peptides listed in Table 13.

5

---

HLA BINDING PEPTIDES AND THEIR USES

## ABSTRACT OF THE DISCLOSURE

5 The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.

SF 175521 v1

10

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
220

### DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: the specification of which   X   is attached hereto or        was filed on                      as Application No.                      and was amended on                      (if applicable).

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56. I claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

#### Prior Foreign Application(s)

Country	Application No.	Date of Filing	Priority Claimed Under 35 USC 119

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Application No.	Filing Date

I claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Date of Filing	Status
08/205,713	March 4, 1994	pending

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Hector A. Alicea, Reg. No. 40,891	Joe Liebeschuetz, Reg. No. 37,505
Randolph T. Apple, Reg. No. 36,429	Jeffry S. Mann, Reg. No. 42,837
Kevin L. Bastian, Reg. No. 34,774	Annette S. Parent, Reg. No. 42,058
Guy Chambers, Reg. No. 30,617	Steven W. Parmelee, Reg. No. 31,990
Karen B. Dow, Reg. No. 29,684	Brian W. Poor, Reg. No. 32,928
Gregory P. Einhorn, Reg. No. 38,440	Margaret A. Powers, Reg. No. 39,804
Susan K. Faris, Reg. No. 41,739	Jonathan Alan Quine, Reg. No. 41,261
M. Henry Heines, Reg. No. 28,219	Timothy L. Smith, Reg. No. 35,367
Laurence J. Hyman, Reg. No. 35,551	William M. Smith, Reg. No. 30,223
Tom Hunter, Reg. No. 38,498	Joseph P. Snyder, Reg. No. 39,381
Jeffrey J. King, Reg. No. 38,515	John R. Storella, Reg. No. 32,944
	Eugenia Garrett-Wackowski, Reg. No. 37,330
	Ellen Lauver Weber, Reg. No. 32,762
	Kenneth A. Weber, Reg. No. 31,667
Epimmune, Inc. Timothy J. Lithgow, M.D., J.D. Reg. No. 36,856	P. Ben Wang, Reg. No. 41,420

Send Correspondence to:	Direct Telephone Calls to: (Name, Reg. No., Telephone No.)
Ellen Lauver Weber <b>TOWNSEND and TOWNSEND and CREW LLP</b> <b>Two Embarcadero Center, 8<sup>th</sup> Floor</b> <b>San Francisco, California 94111-3834</b>	Name: Ellen Lauver Weber Reg. No.: 32,762 Telephone: 415-576-0200

Full Name of Inventor 1:	Last Name: SETTE	First Name: ALESSANDRO	Middle Name or Initial:
Residence & Citizenship:	City: La Jolla	State/Foreign Country: CA	Country of Citizenship: Italy
Post Office Address:	Post Office Address: 5551 Linda Rosa Avenue	City: La Jolla	State/Country: CA Postal Code: 92037
Full Name of Inventor 2:	Last Name: SIDNEY	First Name: JOHN	Middle Name or Initial:
Residence & Citizenship:	City: La Jolla	State/Foreign Country: CA	Country of Citizenship: US
Post Office Address:	Post Office Address: 8541 D. Villa La Jolla Drive	City: La Jolla	State/Country: CA Postal Code: 92037
Full Name of Inventor 3:	Last Name: KAST	First Name: W.	Middle Name or Initial: MARTIN
Residence & Citizenship:	City: Leiden	State/Foreign Country: The Netherlands	Country of Citizenship: The Netherlands
Post Office Address:	Post Office Address: Maria Rutgersweg 106	City: Leiden	State/Country: Netherlands Postal Code: 2331 NX
Full Name of Inventor 4:	Last Name: SOUTHWOOD	First Name: SCOTT	Middle Name or Initial:
Residence & Citizenship:	City: Santee	State/Foreign Country: CA	Country of Citizenship: US
Post Office Address:	Post Office Address: 10679 Strathmore Dr.	City: Santee	State/Country: CA Postal Code: 92071
Full Name of Inventor 5:	Last Name:	First Name:	Middle Name or Initial:
Residence & Citizenship:	City:	State/Foreign Country:	Country of Citizenship:

Citizenship:			US	
Post Office Address:	Post Office Address:	City:	State/Country:	Postal Code:
Full Name of Inventor 6:	Last Name:	First Name:	Middle Name or Initial:	
Residence & Citizenship:	City:	State/Foreign Country:	Country of Citizenship:	
Post Office Address:	Post Office Address:	City:	State/Country:	Postal Code:

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor 1  ALESSANDRO SETTE	Signature of Inventor 2  JOHN SIDNEY	Signature of Inventor 3  W. MARTIN KAST
Date	Date	Date
Signature of Inventor 4  SCOTT SOUTHWOOD	Signature of Inventor 5	Signature of Inventor 6
Date	Date	Date